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The increasing diversity of HIV -1 in different geographic regIOns presents a 
challenge for the development of an HIV / AIDS vaccine. Even if proven effective, the 
ability of a vaccine to have cross-subtype and intra-subtype protection remains an 
important question. The aim of the study was to investigate cross- and intra-clade T 
cell immune responses in HIV -1 subtype C-infected individuals. The objectives were 
to genetically characterise full length gag gene sequences from individuals 
chronically infected with HIV-l and then assess the degree of cross-reactive immune 
responses in an ELlS pot assay using peptide reagents based on vaccine candidates. 
Forty HIV-infected antiretroviral therapy naIve individuals were recruited into the 
study. The HIV -1 gag region was amplified and directly sequenced. Phylogenetic 
analysis was performed to determine the subtype of the infecting strain and genetic 
distances calculated between isolate sequences and peptide reagent sequences used in 
immunological assays. Cross-clade T cell immune responses were then examined in 
the peripheral blood mononuclear cells of 39 study subjects in an Enzyme Linked 
Immuno Spot (ELISpot assay). An ELISpot assay making use of a pool and matrix 
approach allowed for detection of responses to peptides spanning the Gag protein 
from two subtype Cs, subtypes B, A and D, based on vaccine candidates. The reactive 
peptides were confirmed in a second ELISpot assay in two individuals. All viruses 
were subtype C viruses and their sequences were not more closely related to each 
other when compared to other subtype C viruses. The p24 region was the most highly 
conserved among study sequences as expected. HIV Gag-specific T cell responses 
were detected in 97.4% (38/39) of the study individuals. All of the individuals who 
had detectable HIV -specific T cell responses recognized Gag peptides based on Cs.A 
and CCH sequences. Interestingly, there was no significant difference in the magnitude 
of T cell response to the two subtype C sequences. The total magnitude of the HIV-
specific T cell responses to the two subtype C sequences was significantly higher than 
that of subtypes B, A and D. 78.9% of the individuals had anti-HIV T cell responses 
to all 5 HIV-l subtypes. 7.9%, 5.3% and 7.9% of the individuals responded to 4, 3 
and 2 subtypes, respectively. All individuals who had T cell responses recognized at 
least two HIV peptide variants. The cross-clade responses were substantial for the 
p24 region of Gag protein. In the individuals where reactive peptides were confirmed, 
HIV -specific T cell responses were directed against peptides with lower intra-clade 













HIV-1 subtype C-infected individuals can mount vigorous intra- and cross-clade 
immune responses against Gag from subtypes A, B, C and D. Therefore, these results 
suggest that vaccines based on these two subtype C sequences may work equally 
well. However, vaccines based on other subtypes might be less effective than clade-
matched vaccines. The data might be useful in making decisions about testing 
candidate vaccines in regions where different HIV -1 subtypes than those in the 
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Chapter 1: Literature review 
1.1. General 
The number of people infected with HIV worldwide is estimated to be 42 million, with 
more than 90% living in developing countries, 10% of whom are in South Africa 
(UNAIDS: AIDS epidemic update 2007). Although antiretroviral therapy has become 
increasingly available, access in Africa remains limited and an effective vaccine remains 
our greatest hope for controlling this epidemic. There is, therefore, a desperate global 
need for a prophylactic HIV vaccine. 
There are a number of major scientific challenges in developing such a vaccine, of which 
genetic diversity is one of them. HIV -1 is a highly diverse virus with at least nine 
subtypes, as well as thirty-four intersubtype circulating recombinant forms which have 
been described to date (http://hiv-web.1an1.gov), of which three, namely CRFOl_AE, 
CRF07 _ BC and CRF08 _ BC, have played a critical role in the Asian HIV -1 epidemic. 
The emergence of unique recombinant forms adds to the enormous genetic diversity of 
HIV-l, which has implications for HIV vaccine deVelopment (Casado et al., 2005; 
Robertson et al., 1995; 2000). Continued monitoring of the genetic diversity ofHIV and 
the global distribution of the different subtypes is necessary to inform vaccine 
development strategies. 
It is not known whether the T cell vaccine concept will b~ successful at inducing strong 
HIV -specific T cell immune responses that can control HIV replication. This is illustrated 
by the recent failure of the Merck Ad5 vaccine in phase lIb vaccine trials, in which 
vaccinated individuals were more susceptible to HIV infection than unvaccinated 
individuals (Cohen, 2007a; 2007b). If the T cell vaccine concept could be successful at 
controlling HIV replication, it is important to know whether the immune responses 
generated could be cross-reactive among the different HIV subtypes. In other words, 
vaccine researchers need to know whether clade (subtype )-matched vaccines are 
necessary, which is of great importance in deciding whether vaccines based on certain 
subtypes can be tested in populations where a different subtype is circulating. 
Although the immune correlates of protection in HIV infection are not fully understood, 
numerous studies suggest that the induction of both HIV -specific cellular and humoral 
immune responses is important for an effective vaccine against HIV. Furthermore, an 
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that arc preferentially reLogni/oo and host genetic factors involved in tho'>C responses 
w!ll be 01' importanec in vaccine development "Ppnmches. The aim of thc study rcported 
in this thesis was to mea~ure cm~s-readi\'e immune responscs to different lilY suhtypes 
in mdividuals in jeLled ,,'ith a single subtype (termed 'cros8-cJade' re-;ponses), in order to 
pr~dict whether a fmure yaceine based on one 8lIh\Yl'e may he cross-reactive, and 
thcrcfore potentially effedive, in a population "here a ditTcrent suhtype i8 circulating. 
J .2. Structure and genomic organization of HIV-l 
The Human Immunodeficiency virus (HIY) belongs to the family of rdroviru~e~, 
suhgroup lentivimscs (Sharp el al .. 2(00), Other lentivlT1.J~e~ include Simian 
ImmlUlodcfieiellCY Vinls (ST\'), Fchne immunodeficiency Virus (FlY), Yisna and 
Caprine Arlhritis-Encephala;s Virus (CAEY), which eausc diseases in monkeys, cat~. 
shcep and goats (Nishimura et ai" 1999: Pa8ick, 1(98), Infection8 with lenliviruscs 
typic<lUy show <I chronic couP.le of dise<l8c, a long period or clinical Imency, persistcnt 
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p24 tht, ,"'0. The ,i,. of "" J][V panicle b arC><Lnd 0.1 n1lcron.'. Ad"",ed rrom GoU" and 
MO!]lai-loicT, 19gg) 
OUhlde or a human cell. my cxists as roughly spherical viral particks or virion 
(Gdderhlom, 1991). The tIIV envelope protein protrudes from the surface of lirions 
giving the appearanc~ or spikes as shown hy the photograph in Fib'llre 1.1 and 
diagrammatically ill Figure 1.2 (a). HIV has a diploid RNA genome approximately 9.7 kb 














VJ R V, 
3' I TR 
Em IW~I 









(;~g p7 Gagp6 
'"' 
'P' 




ItV.' 1 cdl 
l)rulnllS 
III V·1 k Nr\ 
VJ R U, 
""/ 
t'l;ur~ 1.2 (11) i) •• lgl'linHn.1Iic I\:f1"'SO!n lal ,o" .. r Ilk ",n. p ho l"gio: "lflKlurc nf Iho; H IV. 1 ,"moo 
1"',ln:l" In. Iral","" ~;",.n. 'M lilln'" 1>,,,, 10<,,,.,,,, ... , ... h .... .dori_ 1'1"01 Ioobr)"", Th~ , .. met," ;:I)'''I''''I~'' 
"f'llcs rolllp<»fJ "r ~p ' 2" I ...... __ J I" u~ Iop ,d hd a)el IMtttbranc h} ~ I "'" eA~ Oft ,he' .. I ..... ... ,fac( a .. " 
_ 'n,,~,<!d ,n Ihe ltll.h"",nl " I tho: .in.,.. '0 C().t cell> d"-'''!t ."tOC'OOIL (h ) The " rg"'" ';lt,,,n (II ll 1V- 1 
S"nltm". Tlw UI ... • t 1""0"'''1 ::(""" .. ,(I.1lb) is ro'"p<Ke<l of lIute !"IIOS (iI.li<:ind ;vId bold) 11\:11 "''' ' bIlL . .. 
..... I" .. I<>h~ u"m,n-' """,Ill> I L 1"1« " , .... II ..... """" "'~d,ns ("dill"" ~na"'" ,. led •• I ~ "''', ...... n " J:<IJ: !."tI>( I., 
Innstltfll I~M" 11"1 >n"~I\lI",J <Jag. .,...,.,~ .. ,I'r 55 -, '" hie .. " d ca ."'" mt" !tid"" Wi n c ... i<l Ip~J I. ,""If" 
CMlS Iht ,on l i,n ~1c slraodod I(.'IA ~."",nc). 1'7 (nude"""",oJ "ill'''' h;nJ, " , d.e HI\' 1',,,:h ! ,,'Il !.I~IIOI,.' ,n"31 
RNA ~nd .. ,,,rr,, Of'" fOf lRC(IrpN .II "'" "r RNA (JII" "iri"",) . .... J p(> Ip2 .no:! p! "'" 'I""or .....,...,001 Ttw J'<'I 
It ..... 1ro" ,I,~w ." (. j ) ,,1>ofo;.",,1 fr:t ..... ' Joilt .. . (ja~-l'oI ",ee.......,.. pol~J1<t't,de Wt Ylel<l$ If>( IflIIi't roz:. n • ., 
"' .. ..,., ~(W\s.;r~t".., lilT). '"lCr'" ,INI .nd !'rote.", II-'fl) IIJ'O" <1<-.. "."," The ,-n,' ~fI( .MO<le1 OtW;h{)r 
""""W'a! prec .. "'" « n, ~r l ~). "~Kh .. 01"", .. 1 ">I" the ...-ta<:e (,..,120) . ... 1 ",."n",m!>m"" (,..,.,1) 
~I~,;<?()!~in (;"I('Po/ ",II NA, .. . "fI1"'." In <".,,~!< th o r~~~llalory (r .... tot. ""f) ,n" (lIC' ''''''''} ("f" . vf>\'. "") 
prot."" ~"'m dr.,,'., h..., .. on i"I, ~m.""" I,om httjF' h"_,,",, .. ~. 
1.2 b) 1110:<C' protein$ can be divided into three main classes; the major stnKlllrn l proteins 












Chapter I: Liter:>.ture l"C'View 
Vpr, Vif Ilnd Nt'I). The g<:1I(" [~ "t cod~ lor lhe~e J'Toi.eil\~ "r~ located in the cell1r~1 r<'Sioll 
of the integral,'d fQ(11l of IIIV-I, .... hich is r<'f<'fred to as the provmd OKA (.lppro>.lmatc!y 
~"11 kb). U01h cuds ofllus pru\iral ONA are O.mkeu by a lq"'llleJ ~C"l ""'lM:C known a~ lhe 
Ion!.! lemlillal repeats (L T Rs). 
1.2.U. III \' I:~= 
fh is thcslS focllses 011 IIIV-J Gas. a highly immul>Ugenic aJod CUIl. .... "T"\'ed pTl)tcm thill IS 
all ImJXlfl,lnl \aCCII",e immu"''b'l'll included in 10%1 canuithle HIV \JCC'n<'S 11\ 
dc . Ch"plll\:nt , and IQr lhi ~ rc-.. '101l a mor'(' dct.~Ill-d background of (jag ;s provided. j he 1:(1): 
gen<', ~hich ellcompasses L5% of the .iral gC1lOmc. gi.cs rise to a 55 kJlrll"j!('I1 (kj)~) 
(lag ~.·un;or Jlmteln (~dso 1;<IIIe<.l p55) (Gol!lillgCC. 20(1) (FIgure 1.3). Th~ Ciag rrot~ln 
~nd its proteolyt ,caJl y derived maturation products s("rIC as thc major ~truC1ur~ l 
cOmp')11\."T11s 01" I h .. II IV • irjoll (Frced. 1998) . 
.m LTD 
r -"------ y A , 
·N. "I I ., '" I I 
pr55~ II I I III 
" II ' • "~ 
~ " ., " " U,17) 1P2. ) on 
figure. 1.3 A ~hconallc repres.:n[:u ion of PrSS l"'8 and ,IS sub-Jo",." n~. The 1'<'6'''0115 "f,h. 
d,ffnt'" G~ doN,,.. ... c<><dm~ II, UXR:! f~ oon>monl~ .....J r..r"""",,, ,",,,,,, b.,,:d ,,', IIIY_I .... 1Yl'" R) 
04 prOlfll' ~":II."f m .. ,nd" ... c .... ' \ ...... e .. 011''''' • .....J. l\TD i'\L~ino--t...'fru",.l d"""'in). I -Il) tC ..... " y 
Il'j.I«ml\.:>1 do~IJ'''), ... ( . ... ,"" ... >d~ MHR f m"l"'" loom"',*>· ~","l. M (n ... :mht-~"" b,nd,ng .... '''''''n\. [ 
(1",«><, ·'..,.<10""" ,,\ ;u,~ L /1.;11,.-<1"",.,")_ ['he p~4 """ occn ."" ...... Iu t..,. mo ... ""n, • .-, ... c..J ,lun , ... .-. ( ;"l!-
"'!(IOns. 
),17 (mulrl1) 
I he m.1l,i x prol. ~111 j~ 'kr; \'cd Innn the N-tcnninal. myrist ylat~d end 'If p~ 5 :lnd f,mns lh~ 
"cidlbld bl:twwn the C<:>rCS and Ih~ out~r ~nvelop<:. Myristylation is Ilic cO-Inm.~I"l1omti 
adolII1,m or a 14- ~ilroon fany acid (!\lyrislale) that i~ .~'sociilteu with target ing of rrot~1f'Is 
10 mC1\ll1rano.:~. The pl7 rel!\ioll also contains" nudear iocali/<l(IOn u""~li" which 
f;ICililalcs tile I\uclear [nm~f'0rt 01" the viral genome TI,is allO\-\'s HIV to mli:d ",)1)-











Chapter 1: Literature review 
amino acids of Gag and includes the terminal myristate (Zhou et aI., 1994). Deletions in 
the M-domain abolish membrane binding and budding. 
p24 (capsid) 
The p24 protein is a highly conserved region of the HIV Gag protein that forms the 
conical core of viral particles (Gottlinger, 2001). Cyclophilin A, a cellular protein, has 
been demonstrated to interact with p24 and can be incorporated into HIV particles. The 
p24 region has been shown to be essential for the proper folding of the virion proteins 
(Y 00 et al., 1997). It is the p2 domain next to the capsid that has been demonstrated to 
confer sensitivity of the capsid protein to Cyclophilin A binding (Dorfman & Gottlinger, 
1996). 
Nucleocapsid, NC (P7) 
The NC region of Gag is an important gene for the transmission and pathogenesis of the 
virus. It is responsible for specifically recognizing the packaging signal of HIV, 
packaging two copies of the viral genome into progeny virions (Heath et al., 2003; 
• Krishnamoorthy et al., 2003). The protein also protects the viral genome from nuclease 
digestion. It has also been shown to ensure proper annealing of the tRNA Lys primer to the 
primer binding site to initiate reverse transcriptase, in addition to aiding in strand transfer 
hence facilitating reverse transcriptase enzyme function (Freed, 1998; Levin et al., 2005). 
The p7 protein contains one major functional domain consisting of two zinc finger motifs 
that allow the NC to bind the packaging signal. The motifs contain the sequence C-X2-
C~x.-C with critical residues consisting of three cystines (C) and one histidine (H). 
Mutation of these amino acid residues to non-zinc binding residues results in virions 
defective in RNA packaging (Freed, 1998; McGrath et al., 2003). The antiviral effects of 
APOBEC3G (a cytidine deaminase that introduces G-A hypermutations in newly 
synthesized viral DNA) have been shown to be through interaction with the p7 region of 
HIV Gag protein (Alee & Popik, 20(4). HIV vif, an accessory protein has been shown to 
interact with APOBEC3G thereby overcoming the antiviral effects of the enzyme. 
Furthermore, mutations in the p7 protein may lead to lack of antiviral effects by 
APOBEC3G. Therefore, any alterations to the gene may affect transmission and 
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A proline-rich peptide of approximately 6 kDa derived from the C terminus of the p55 
Gag precursor protein is called p6. The p6 region mediates the interaction between p55 
Gag and the accessory protein Vpr, leading to Vpr incorporation into the assembling 
virions (Zhu et al., 2004). The protein also contains the late domain which is required for 
the efficient release of budding virions from an infected cell. Mutations of this protein 
have been shown to prevent the release of budded virus particles from the cell surface 
(Freed, 2002). 
1.2.1.2. Pol 
During the replication cycle of HIV-1, the single stranded RNA (ssRNA) genome is 
reverse transcribed by the HIV enzyme reverse transcriptase (RT), coded for by the pol 
gene (Kuiken et a/., 2000). Pol also encodes for the enzymes protease, integrase and 
RNAse H, all of which are essential for replication (Coffin, 1990). Protease processes 
proteins made from HIV's genome so that they can become part of newly fully-functional 
HIV particles (Short et al., 2000). RNAse-H breaks down the retroviral genome after 
being copied into DNA by reverse transcriptase following infection of a cell. The fourth 
Pol protein, Integrase, catalyzes integration of the viral provirus into the host genome 
(Craigie, 2001; Wang et al., 2001). 
1.2.1.3. Env 
Env consists of two proteins, gp120 and gp41. Gp120 is located on the outside of the 
virus while each gp41 molecule is anchored to a gp120 through the membrane. The 
Envelope prote n exists as a trimer and is responsible for recognition of cellular receptors 
and viral entry into cells. 
1.2.2. Regulatory proteins 
1.2.2.1. Tat 
Tat (transactivator) is a 101 kDa regulatory protein that accelerates the production ofHIV 
viral particles. It acts as a transcriptional regulator of viral gene expression by binding to 
the transactivating responsive sequence (TAR) RNA element. This initiates viral 
transcription and! or elongation from long terminal repeat promoter (Roy et al., 1990). 
Tat also up-regulates the expression of all viral genes and promotes the elongation phase 
of HIV-1 transcription, allowing full-length transcripts to be produced (Feinberg et al., 
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differential critical role of Tat for viral infectivity and pathogenesis in different HN-l 
subtypes may differentially modulate the pathogenic properties of the different viral 
subtypes leading to other HIV -1 subtypes being of more globally significant than others 
(Ranga et al., 2004; Siddappa et al., 2006). 
1.2.2.2. Rev 
Rev, a 12.76 KDa protein stimulates the production ofHN particles by up regulating the 
expression of structural genes (gag, pol and env) while down regulating itself and tat 
(Douglas et al., 1997). Rev protein also induces the transition from early phase to late 
phase ofHN infection (Hanly et al., 1989). 
1.2.2.3. Nef 
Negative replication factor (Net) is a 27 kDa protein that retards HN replication by 
downregulation of transcription factors natural factor kappa B (NF-lCB) and activator 
protein one (AP-l) (Bandres et al., 1994; Bandres and Ratner, 1994). Nef also induces 
downregulation of CD4 (Aiken et al., 1994) and HLA class 1 molecules (Collins et al., 
1998) from the surface of HN infected cells which impairs T cell function, thereby 
helping the virus to invade host immune response (Schwartz et al., 1996). In addition, 
Nef interferes with T cell activation by binding to various proteins that are involved in 
intracellular signal transduction pathways (Peter, 1998). 
1.2.3. Accessory proteins 
1.2.3.1. Vif 
Virion infectivity factor (Vit) is a 23 kDa protein which increases the infectivity of the 
HN particle. Vif interacts with a cellular protein that belongs to the host's internal 
cellular defence, known as apolipoprotein B mRNA editing enzyme catalytic 
polypeptide-like 3G (APOBEC3G), which leads to the degradation of the protein (Opi et 
al., 2007). APOBEC3G is an intracellular antiviral protein that makes virions non-
reproductive by deaminating the minus-strand of the viral reverse transcripts introducing 
numerous G to A mutations. Vif acts by preventing the incorporation of APOBEC3G into 
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1.2.3.2. Vpr 
Viral protein R (Vpr) is a 15 kDa protein that accelerates the production ofHN proteins 
by arresting infected cells at the G2 phase of the cell cycle (Jowett et ai., 1995), 
inhibiting cell division by mitosis (Planelles et ai., 1995). It also facilitates the nuclear 
localization of the preintegration complex that is the agglomeration of viral RNA, RT and 
Integrase proteins which must fonn in order for the HN genome to be integrated into the 
host cell's genome (Miller & Sarver, 1997). 
1.2.3.3. Vpu 
Viral protein U (Vpu) is a 17kDa protein which is not present in HN-2, is involved in the 
assembly of new virus particles and facilitates budding (Deora and Ratner., 2001). The 
fonnation of Env-CD4 complexes interferes with viral assembly. Vpu down-modulates 
CD4 in the endoplasmic reticulum therefore reducing the likelihood of superinfection and 
is also involved in Env maturation. This reduces the fonnation of the Env-CD4 
complexes. Vpu is not found in virions (Willey et ai., 1992). 
1.3. Genetic diversity of HIV-l 
HN is divided into two main types, HN-l and HN-2. Phylogenetic analyses have led to 
the classification ofHN-l into three genetic groups, namely a major group (group M), an 
outlier group (group 0) and a non-Mlnon-O group (group,N) (Robertson et ai., 2000). 
HN -1 group M, which is responsible for the global pandemic, is further subdivided into 
nine different genetic subtypes or clades designated by the letters from A-D, F-H, J and K 
(Robertson et ai., 2000). Subtypes are genetically defined lineages that can be resolved 
through phylogenetic analysis of the HN -1 group as well-defined subtypes, or branches 
in a tree. Currently, strains belonging to the same subtype can differ by up to 20% in the 
env gene and inter-subtype genetic distances can reach up to 35% (Shankarappa et ai., 
1999). HN is continually evolving and the epidemic is becoming more complex with 
recombination. 
Recombination occurs frequently and a circulating recombinant fonn (CRF) is a virus 
that carries sections of two or more subtypes in a mosaic genome (Fang et ai., 2004). A 
recombinant lineage is designated a CRF when related fonns are found in multiple 
epidemiologically unlinked individuals. To date, 19 CRFs have been identified (Casado 
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emerging epidemics. For example CRFOl_AE and CRF02_AG are dominant CRFs found 
in Thailand (Xiridou et al., 2007) and West Africa respectively (Fischetti et al., 2004). 
HIV-l subtypes and CRFs are unevenly distributed throughout the world, with the most 
widespread being subtypes A, B and C, contributing approximately 72% of circulating 
viruses in 2004 (Hemelaar et al., 2006). Overall, it is estimated that HIV-l subtypes and 
CRFs play different roles in the regional sub-epidemics. Subtype C strains, which are 
predominant in Ethiopia, India, China and southern Africa (Figure 1.4 a), account for 
50% of all infections worldwide (Figure 1.4 b) which has increased from 47.2% in 2000 
(Osmanov et al., 2002). Subtype A is the predominant subtype in East Africa and 
accounts for 12% of infections worldwide, B is prevalent in Europe, Brazil, the United 
States of America, Canada, Australia and Haiti as well as in South African men who have 
sex with men (van Harmelen et al., 1997) and accounts for 10% of infections worldwide 
compared to 12.3% from year 2000 data (Osmanov et al., 2002), and D and G are mainly 
found in central Africa and are responsible for 3% and 6% of worldwide infections, 
respectively (Figures 1.4 a and b). Subtypes F, H, J and K together are responsible for 
0.94% of infections worldwide (Hemelaar et al., 2006). 
The CRFO 1_ AE, predominant in Thailand (Xiridou et al., 2007), and CRF02 _ AG found 
mainly in Gabon, Ghana and Nigeria (Fischetti et al., 2004), are responsible for 5% of 
infections worldwide. CRF03 _ AB only plays a small role in Eastern Europe and Central 
Asia. Other recombinants accounted for the remaining 8% of infections worldwide. All 
. recombinant forms taken together were therefore responsible for 18% of infections 
worldwide (Figure 1.4 b) (Hemelaar et al., 2006), illustrating the highly diverse and 
complex nature of the HIV epidemic. 
Of all HIV -1 infections worldwide, 64% are present in sub-Saharan Africa. Fifty-six 
percent of sub-Saharan African infections are a result of subtype C viruses (Butler et al., 
2007). The remaining smaller proportions are caused by subtype A (14%), subtype G 
(10%), CRF02 _ AG (7%) and 9% other recombinants (Hemelaar et al., 2006). There are 
five main sub-regions of sub-Saharan Africa and they also show marked differences in 
distribution of HIV -1 subtypes and recombinants as well as their global contributions. 
Southern Africa accounts for 30% of all global infections and Ethiopia contributes 4%. 
The HIV -1 infections from these two regions of Africa are contributed mainly by subtype 
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infections worldwide respectively and the other 29% coming from unique recombinant 
forms. 
Central Africa contributes 5% of infections worldwide with HIV -1 subtype A being the 
most prevalent, accounting for 38% of all the infections in the region (Butler et al., 
2007). However, subtype D prevalence is also increasing. Overall, the countries in this 
region all harbour a great diversity of subtypes and recombinants, but differ in the 
subtype that dominates. In North Africa and the Middle East, the main subtypes are 
subtype D (47%) and C (29%). 
The remaining proportion comes from subtypes A (6%), B (7%), as well as 9% of 
recombinants. Altogether, these subtypes and recombinants contribute 1 % of global HIV-
1 infections (Hemelaar et al., 2006). 
Diversity may have an impact on vaccine efficacy and therefore there is need to be able 
to identify viral regions that with the capability of eliciting strong long lasting cross-
reactive immune responses across the different HIV subtypes and CRFs. These cross-
reactive responses might translate to vaccine induced cross-reactive immune responses. 
In the case that those regions fail to elicit cross-reactive immune responses, this would 
suggest the need for clade-matched vaccines. 
1.4. HIV-1 variability 
Within an individual, there is a mixture of closely related yet genetically distinct genomes 
referred to as quasispecies (Eigen, 1993; 1996). HIV -1 strains within an individual can 
differ by as much as 10% in sequence (Shankarappa et al., 1999), while between 
subtypes (intersubtypes) distances can be as much as 35% in the env gene. 
1.4.1. Mechanisms of HI V-I evolution 
The enormous variability of HIV -1 is the result of two main mechanisms, mutation and 
recombination. Forces that drive the evolution of HIV-l include immune selection 
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1.4.1.1 Mutation 
HIV has a vast evolutionary potential due to a high rate of point mutations, namely 3xlO-5 
substitutions per site per generation (Mansky and Temin, 1995). The high error rate of 
HIV RT results in misincorporation of nucleotides and is a major source of mutations 
throughout the viral genome and a determinant for rapid viral evolution (Ji et ai., 1994; Ji 
and Loeb, 1994). Rapid evolution of HIV-l has been shown to correlate with rapid 
disease progression (Mikhail et ai., 2005; Mullins & Jensen, 2006), although it is not 
clear whether the virus is evolving due to high viral loads or whether it is the evolution 
resulting in loss of control that lead to high viral loads. 
1.4.1.2 Recombination 
Genetic recombination is also a source of major variation. Recombination occurs at an 
average rate of 3 events per genome per round of replication, ranging from 2-20 
crossovers (Hu & Temin, 1990). Other studies have found recombination rates of2.8 per 
genome per viral replication cycle (Zhuang et ai., 2002). Detectable recombination 
requires infection with more than one virus at the cellular level. Recombination can occur 
between viruses of the same subtype (intra-subtype) (Philpott et ai., 2005) or viruses of 
different subtypes (inter-subtype). Inter-subtype recombination is a result of the co-
packaging of viral genomes from two genetically distinct viruses into a single viral 
particle in the next cycle of infection. Intra-subtype recombination has been found in 47% 
of sequences in a subtype C epidemic (Rousseau et ai., 2007). Recombination is most 
frequently identified when it is between subtypes (Charpentier et ai., 2006; Yirrell et ai., 
·2002). 
1.4.2. Forces driving the variability of HIY-l 
Host immune pressure and availability of target cells are both factors driving variability 
of the virus. The rapid turnover of HIV -1 is also a contributor, as HIV -1 has been shown 
to produce 108 to 109 virions per day (Ho et ai., 1995; Wei et ai., 1995), although it is 
estimated that 27-66% are defective (Sanchez et ai., 1997). 
1.4.2.1 Immune selection pressure 
The extensive global diversity of HIV is one of the major challenges facing the 
development of an effective vaccine. It has been suggested that HIV shows stronger 
effects of positive Darwinian selection (a phenomenon whereby there is a selective 
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In both HIV and SIV models, there is evidence of positive selection exerted both by 
neutralizing antibodies (Greenier et al., 2005; Richman et al., 2003; Zhang et al., 1993) 
and by the host immune cellular immune response (Allen et al., 2000; Barouch et al., 
2002; Borrow et al., 1997). Studies on the adaptation of HIV -1 to CD8+ T cell responses 
at the population level (Moore et al., 2002) are evidence of the role of immune selection 
pressure in driving the global sequence variability of HIV. The level of this sequence 
variability is different for different HIV genes. This is because certain mutations in some 
genes such as gag, a structural gene, pose a fitness cost to the virus and this is supported 
by studies which have shown the reversion of HIV -1 virus to wild type when transmitted 
to HLA mismatched individuals, suggesting a cost to the viral replicative capacity that 
may be incurred by acquisition of the relevant escape mutation (Barouch et al., 2005; 
Fernandez et al., 2005; Friedrich et al., 2004; Matano et al., 2004). However, the env 
gene is a structural gene but there is rapid evolution which is clearly associated with 
strong autologous neutralizing antibody responses (Liang et al., 2003; Price et al., 1997; 
Wei et al., 2003). Therefore, greater variability ofHIV is created when the virus is trying 
to escape from immune pressure. The more the viral regions targeted by HIV -specific T 
cells, the more the virus will mutate in trying to escape from the immune pressure leading 
to more variability of the virus within an individual as well as within populations when 
these variants are transmitted. 
1.4.2.2 Availability of target cells 
During the primary stage of infection and the asymptomatic phase, HIV -1 has been 
. shown to predominantly use the CCR5 coreceptor (Connor et al., 1997). The CCR5 
coreceptor utilizing virus that results is referred to as the R5 virus. On the other hand, 
during the late symptomatic stages of HIV infection, the virus may evolve to show 
increased tropism for CXCR4. This phenotypic switch has been shown to coincide with 
the first immunological and clinical signs of diseases progression (Connor et al., 1997). 
The resulting CXCR4 coreceptor utilizing viral strain is referred to as X4 virus. The 
availability of different cells expressing the receptors required for HIV -1 infection, that is 
CCR5 and CXCR4-expressing cells, and the switch from R5 to X4 are evidence for 
genetic variation (Overbaugh & Bangham, 2001). However, this variation is found in a 
small gp120 V2 region of the env gene (Jansson et al., 2001). Therefore the availability 
of CXCR4 co-receptors will select for the X4 viruses that utilizes the CXCR4 coreceptor 
during the course of HIV infection. However, in some individuals the X4 viruses may 
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(Doms & Peiper, 1997). Therefore, the more the cells bearing specific receptors used by 
certain viruses for infection, the more the infection rates and viral turnover of those 
viruses leading to selection favouring those viruses. 
1.5. Immune responses to HIV-l 
There is a need to better understand the immune responses that occur during the course of 
HN-1 infection to identify immune responses responsible for viral control. For the past 
20 years, researchers have been focusing on different aspects of the immune system to 
determine the immune correlates of HN control. While earlier studies have looked at the 
breadth and specificity or magnitude of the immune response and their association with 
disease outcome, more recent studies have focused on the functionality of the immune 
response, to identify the qualitative features associated with viral control. 
1.5.1. Cellular immune response to HIV-l 
Researchers are currently focused on developing vaccine candidates that will stimulate 
cellular immune responses. Virus-specific CD8+ T cells have been implicated in the 
control ofHN. HN-specific CD8+ T lymphocytes have been found in large numbers in a 
variety of anatomic compartments in both HN -infected humans and SN -infected 
macaques (reviewed in Letvin and Walker 2003). Evidence of the importance ofCD8+ T 
cells in controlling replication has been illustrated in th~cdepletion of CD8+ T cells in 
macaques infected with SN which leads to a sharp increase in viremia (Schmitz et al., 
. 1999). Also, a clear temporal association between the expansion ofHN-specific CD8+T 
cells and viral load reduction was demonstrated in SN-infected macaque models 
(Kuroda et al., 1999; Yasutomi et al., 1993) and in humans (Borrow et al., 1994; Koup et 
al., 1994). Long term non-progressors (LTNPs; those people who take more than ten 
years to progress to disease) have strong T cell responses to HN (Gea-Banacloche et al., 
2000; Maecker & Maino, 2003; Migueles et al., 2000; Rodes et al., 2004). Further 
evidence of the importance of CD8+ T cells has been obtained from studies of individuals 
who are exposed to the virus but remain uninfected (referred to as highly exposed, but 
persistently seronagative (HEPS) individuals). These individuals were shown to have 
CD8+ T cell responses to HN-1, suggesting that the cellular immune response playa role 
in the prevention of infection (Promadej et al., 2003; Rowland-Jones et al., 1998). 
However, these individuals must have been transiently infected for them to have HN-
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controlling HIV infection in some individuals, although viral replication is not fully 
contained in most infected people. 
The acquisition of the capacity to stimulate CD8+ T cells by antigen presenting cells has 
been shown to involve CD4+ T cell help (Xiang et a!., 2005). Furthermore, CD4+ T cells 
are necessary for clonal expansion of CD8+ T cells and their differentiation into cytotoxic 
T lymphocytes (Janssen et ai., 2003), as well as for maintaining memory of CD8+ T cells 
after acute infection (Sun and Bevan, 2003). The magnitude of CD4+ T cell proliferation 
and IL-2 production by CD4+ T cells has been shown to correlate with the clinical status 
of HIV -infected humans and SIV - or SHIV -infected monkeys (Rosenberg et ai., 1997; 
McKay et ai., 2003). Thus HIV -specific CD4+ T cell responses are also important for 
viral control. 
The HIV regIOns targeted by the cellular immune response will help in choosing 
immunogens for vaccine design. Most HIV -infected individuals mount robust T cell 
responses to HIV (Addo et ai., 2003; Betts et ai., 2001). All HIV proteins are 
immunogenic and HIV -infected individuals have responses in the order Nef> Gag> Pol 
> Env > Vif> Rev> Vpr> Tat> Vpu (Masemola et ai., 2004). Generally, studies have 
shown that Gag and Nef are the most immunodominant HIV proteins. Individuals have T 
cell responses to a median of 14 epitopes (range 2-42) across the HIV proteome (Addo et 
ai., 2003). 
. The identification of immune correlates of viral control is important in HIV vaccine 
development. In an effort to identify immune correlates of HIV control, studies have 
looked at the magnitude and breadth of HIV -specific T cell responses and their effect on 
either the number of CD4+ T cells, rate of CD4+ T cell decline or viral load (Addo et ai., 
2003; Masemola et ai., 2004; Peretz et ai., 2005). In one study, fifty seven individuals 
were screened for HIV -specific T cell responses using a matrix of 504 overlapping 
peptides spanning the entire expressed HIV genome using an ELlSpot assay (Addo et ai., 
2003). In this study, neither the breadth nor the magnitude of total HIV -specific T cells 
correlated with viral load. In another study on subtype C-infected individuals, the breadth 
of the T cell responses did not correlate with viral load (Masemola et ai., 2004). 
However, the magnitude of HIV -specific T cells in these individuals had a weak positive 
correlation with viral load. This was also found in another study of HI V-infected children 
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correlate of immune control of the virus. These results are further supported by other 
studies which demonstrated that there is no significant difference in the breadth and 
magnitude of HIV -specific T cell responses among typical, fast and slow progressors 
(Peretz et al. 2005), and that the overall frequencies of HIV -specific T cell responses do 
not correlate with viral load and are therefore not the determinant of immune-mediated 
protection in HIV infection (Betts et al., 2001). 
The majority of the aforementioned studies measured a single functional of the cellular 
immune response, namely the production of IFN-y. It is of importance to identify the 
functional nature of T cells that are responsible for HIV control, so that vaccine 
immunogens can be designed to induce those functions. T cells have the capacity to 
secrete multiple cytokines or chemokines, to degranulate and to proliferate. A recent 
study found that L TNPs possess a higher proportion of CD8+ HIV -specific T cells 
positive for four and five functions than progressors (Betts et al., 2006). Thus multiple 
immune functions by HIV -specific T cells may be important for viral control. 
An important finding of several studies on the cellular immune response to HIV is the 
importance of the Gag protein. A number of studies, performed in individuals of diverse 
ethnicities, have suggested that Gag-specific T cell responses could be especially 
important in viral control (Ogg et al., 1998; Buseyne et al., 2002; Edwards et al., 2002; 
Novitsky et al., 2002; Masemola et al., 2004; Ramduth et al., 2005). In a study of 
chronically infected individuals, CD8+ T cell responses ~ere equally distributed among 
. Gag, Pol and the regulatory and accessory proteins, but with Gag being a dominant target 
for CD4+ T cells (Ramduth et aI., 2005). In this study, no consistent relationship was 
found between the magnitude of virus-specific CD8+ or CD4+ T cell responses and viral 
load. However, gag responses were associated with lower virus loads. Another study 
showed that the magnitude of functional CD8+ T cell response to the Gag protein is 
inversely correlated with viral load (Edwards et al., 2002). These results are further 
supported by studies which have shown that it is not the recognition of Gag proteins that 
is associated with control of viremia but is the preferential targeting of Gag that was 
significantly associated with viral control (Masemola et al., 2004; Zuniga et al., 2006). 
Other studies have further dissected the Gag response into its three main regions and 
found that the p24 region of Gag is the most immunodominant region of this protein 
(Geldmacher et al., 2007). A large cross sectional study further confirmed these results. 
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while that of Env-specific responses with high viremia (Kiepiela et al., 2007). In this 
study it was the breadth of Gag-specific response that was associated with decreasing 
viremia and this correlation was not associated with the HLA type of the individuals. 
Thus, specificity and function of the immune response may be more important than 
overall magnitude and breadth. It is thus important to have a clear understanding of 
cellular immune responses against HIV, as this will make important contributions to HIV 
vaccine development. 
1.5.2. Host genetic factors -The role of the Human Leukocyte Antigen (HLA) in the 
pathogenesis of HIV -1 infection 
The task of designing an effective vaccine is made difficult by both the genetic diversity 
of the virus as well as the diverse human leukocyte antigen (HLA) backgrounds of 
individuals in different populations. An important consideration in understanding cellular 
immune responses to HIV -1 infection is the role played by HLA molecules, through 
which CD8+ T cells and CD4+ T cells recognize viral epitopes . 
HLA class I molecules are involved in the presentation of immunogenic peptides to CD8+ 
T cells while HLA class II molecules present immunogenic peptides to CD4+ T cells 
(Gebe et al., 2002). HLA class I molecules involved in peptide presentation are classified 
into HLA-A, -B, -C, while as HLA class II are classified into HLA-DP, -DQ and -DR. 
HLA class III molecules are unrelated to peptide presentation. The type of peptide 
fragment that binds to a particular HLA is a function of the chemical nature of the groove 
for that specific HLA molecule and the sequence of the peptide (Reche & Reinherz, 
2003). 
Different populations and ethnicities express different HLA alleles (Ferrari et al., 2004; 
Wadee & Dunn, 1991; Watkins et al., 1992; reviewed in Stephens, 2005). Even in 
individuals of the same ethnicity, particular HLA alleles expressed differ among 
individuals (du Toit et al., 1990a; 1990b). An allele that is common in one population 
may be rare in another population. Some alleles are limited to particular ethnic 
populations, while others are widely shared among ethnically distinct populations. 
Previous studies have shown that HLA-A30, -A68, -BI5, -B42 and -B58 are commonly 
found in Zulu and Xhosa South Africans but are less frequent in Caucasians (Marsh, 
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population and less frequent in The Zulu and Xhosa people. HLA-All is a common HLA 
allele in coloured, but virtually absent in Xhosa people (du Toit et al., 1987). 
Interestingly, HLA-All is also common in south-East Asia and specifically Thailand 
(Lynch et al., 1998). Another example is the allele HLA-A36 that is found only among 
individuals of African descent. HLA-A2 is among the most common HLA types in all 
populations (Chandanayingyong et al., 1997). 
The extent to which polymorphism occurs is different for different HLA molecules. For 
example, within the HLA class I molecules, polymorphism is more common among 
HLA-B alleles than HLA-A or HLA-C alleles. There are 563 HLA-B alleles, 309 HLA-A 
alleles and 167 HLA-C alleles described, showing that the HLA-B locus is diversifying 
more than the other loci (Kiepiela et al., 2004). 
As HLA class I molecules bind fragments of viral proteins and present these to immune 
cells to initiate responses, the particular fragment of a virus that is immunogenic for T 
cells and the magnitude of virus-specific T cell responses are determined in part by the 
HLA class I molecule expressed in an individual. For example, the SL YNTVATL (SL9) 
fragment of HIV -1 Gag binds to the HLA-A2 molecule and presents it to immune cells, 
resulting in a relatively reproducible high-frequency Gag-specific T cell response in 
HLA-A2-positive individuals (Schmitt-Haendle et al., 2005). 
There are now data that certain HLA types, including HLA B57 (Altfeld et al., 2003; 
. Stewart-Jones et al., 2005), B27 (Stephens, 2005), B5801 (Gao et al., 2001; Migueles et 
al., 2000) and B63 (Frahm et al., 2005) are associated with better disease outcome 
(Altfeld et al., 2006). It may be that these HLA molecules are favouring the selection of 
variants that have escaped T cell immune pressure and have lower replication capacity 
(Martinez-Picado et aI., 2006). On the other hand, HLA B35, B5802 and Cw*04 have 
been shown to negatively affect the outcome of disease (Walker & Korber, 2001). This 
might be due to HLA molecules favouring escape mutants with higher replication 
capacity resulting in higher viral set points. 
Studies have shown that there is differential contribution of different HLA molecules to 
the total anti-HIV cellular immune response and HLA-B molecules were shown to playa 
dominant role in shaping the co-evolution of HIV -1 and HLA molecules (Kiepiela et al., 
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in the containment of HIV. This locus was shown to contribute the most to the total 
cellular immune responses against HIV. Those viral genes whose peptides are presented 
to T cells have strong immune pressure exerted on them. There is a strong selective 
pressure for survival of HIV mutants that escape the T cell response and those mutants 
that are stable are transmitted and accumulate in the population (Goulder & Watkins, 
2004; Leslie et aZ., 2005). There are studies which suggest that HIV adapts to the most 
frequent HLA alleles in a population and this provides selective advantage for those 
individuals who express rare alleles (Trachtenberg et aZ., 2003). 
Different HLA molecules can present similar or identical viral epitopes despite their 
polymorphism, and have therefore been grouped into at least nine major HLA supertypes, 
based on analysis and subsequent clustering of their peptide binding repertoire 
(Doytchinova et aZ., 2004; Kangueane et aZ., 2005; Sette & Sidney, 1999). This may be 
important for candidate vaccines which do not contain whole proteins but just parts of 
genes or epitopes in order to make predictions on whether they will be effective in 
particular populations expressing particular HLA types. 
Given the extensive polymorphism known to exist within HLA and even more genetic 
variation to be revealed as more populations are studied, it may be important to identify 
those viral epitopes that can be recognized by individuals with different HLA 
backgrounds and which are conserved across HIV -1 subtypes. These epitopes may be 
important for inclusion in candidate vaccines. 
1.5.3. HIV Cross-clade cellular immune responses in HIV -1 infected individuals 
Given the genetic diversity of HIV and its rapid evolution rate, the selection of suitable 
antigens and epitope variants is important in the design of an effective vaccine. One way 
to overcome this obstacle is to design HIV immunogens able to induce broadly cross-
reactive cellular immune responses that can recognize a wide selection of different viral 
quasispecies. An immune response in an individual infected or vaccinated with one HIV-
1 subtype, that is cross-reactive to a different HIV subtype, will be referred to here as a 
'cross-clade' immune response. For a vaccine to be effective, T cell responses must 
successfully combat a diverse array of viral variants, including within and between viral 
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Studies conducted thus far have detected high frequencies of HIV -specific T cells that 
clearly have the ability to cross-recognize different HIV -1 strains and subtypes. However, 
in most early studies, cross-recognition was either assessed for a limited number of 
selected epitopes (Cao et al., 2000; Fukada et al., 2002; Rutebemberwa et al., 2004), or at 
the protein level in chromium release assays using cells infected with vaccinia virus 
constructs expressing whole HIV proteins (Buseyne et al., 1998; Cao et al., 1997; Ferrari 
et al., 1997). These studies were thus limited because they could not determine the degree 
of cross-reactivity of HIV -specific T cells at the single epitope level. More recent studies 
have looked at cross-clade immune responses using sets of overlapping peptides covering 
whole functional proteins or the entire expressed HIV genome, and have been more 
informative. For cross-clade studies to be informative in vaccine design, it is important 
also that they determine the degree to which different viral subtypes are cross-recognized 
in individuals infected with different subtypes, that is the frequency of recognition of 
different HIV subtypes in different populations with different HLA backgrounds. 
In one study, cellular immune responses to HIV clades A, B and C were assessed in a 
cohort of 250 subjects infected with these different HIV -1 subtypes from Brazil, Malawi, 
South Africa, Thailand and the United States (Coplan et al., 2005). In this study, cross-
clade cellular immune responses were substantial for Nef and lower for Gag among these 
subtypes, with the fraction of homologous subtype's responses to the heterelogous 
subtype's responses (referred to as cross-clade reactivity ratios) being 0.97 and 0.67, 
respectively. These reactivity ratios were defined as the fraction of cellular immune 
response to a heterelogous subtype (the subtype not responsible for infecting an 
individual), compared to a homologous subtype (the subtype responsible for infecting the 
same individual). This difference in reactivity ratios between these proteins was found to 
be significant (Coplan et al., 2005). These results were further supported in a larger 
cohort of 363 (Gupta et al., 2006). 
The degree of cross-clade HIV -specific T cell responses to specific epitopes across the 
entire HIV proteome was investigated by Yu et al (2005). Twenty-seven chronically 
clade B-infected individuals, were tested for responses to peptides based on subtypes A, 
B and C. Although there was preferential recognition of the peptides based on the 
infecting subtype (subtype B), there was no significant difference in the total magnitude 
and breadth of HIV -specific T cell responses to peptides spanning the entire HIV 
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proportion (34%) of detected HIV-specific T cells showed cross-reactivity among the 
three HIV -1 subtypes. In addition, broadly cross-reactive T cell responses were 
preferentially directed against those viral regions with low intra-clade entropy and 
simultaneously high inter-clade homology such as Gag, Nef and Pol, with Gag being the 
most cross-reactive protein (Yu et al., 2005). 
Sequences that are representative of all the HIV -1 subtypes (referred to as consensus or 
ancestral sequences) can be generated using phylogenetic methods. A recent study 
assessed cross-dade immune responses to consensus subtype A, B,C as well as group M, 
ancestral M and virus based subtype B HXB2 Gag peptides in 43 subtype B-infected US 
subjects and 13 subtype C-infected Zambians subjects (Bansal et al., 2006). This study 
was an effort to determine if minimizing the genetic distance between HIV sequences 
infecting individuals and HIV sequences includes in vaccine candidates would have an 
impact on cross-clade responses. The study demonstrated sequences that are 
representative of all the HIV -1 group M subtypes can be used to evaluate HIV Gag-
specific responses. However, this idea as a vaccine concept needs to be tested in primate 
(human or non-human) vaccine recipients to determine whether responses elicited by a 
consensus immunogens are more cross-reactive than those seen by a single viral isolate 
(Bansal et al., 2006). 
Bioinformatics tools can be used to look for reasons for lack of cross-clade recognition to 
some peptides. In these theoretical approaches, combinatorial libraries were used to 
. derive HIV -1 Gag p 17 SL9 epitope mimics (Boggiano et al., 2005). Laboratory 
assessment of responses to these mimics found that those mimics that have amino acid 
changes at the conserved F pocket anchor residues are less frequently cross-recognized. 
In addition, changes in T cell receptor contact sites have been shown to abrogate the 
recognition of peptides by HIV -specific T cells (Malhotra et al., 2007). Peptide variations 
outside the HLA anchor residues of the epitopes have been shown to have less impact on 
cross-clade recognition (Geels et al., 2005). 
Therefore, HIV -specific T cells have been shown to frequently recognize peptides based 
viral subtypes that are different from the infecting virus. Studies have shown that those 
viral regions that are conserved among the different HIV -1 subtypes such as the gag gene 
are more frequently cross recognized than those that are less conserved. Thus cross-clade 
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HLA class I profile of the infected or vaccinated host. The generation of an HIV vaccine 
designed to elicit HIV -specific T cell activity must take these factors into account to 
prime effective intra- and inter-clade T cell reactivity. 
1.6. HIV Vaccine approaches and vaccine-induced cross-clade 
immune responses 
HIV has proved a difficult pathogen to develop a vaccine against. The development of 
such a vaccine has encountered a number of scientific challenges, including an 
incomplete understanding of the immune correlates of protection, the limitations in 
animal challenge models, and the significance of genetic and immunologic variability of 
HIV strains for potential vaccine candidates. It is unclear whether viral diversity together 
with HLA polymorphisms found in different populations will limit broadly reactive 
cellular responses which are an important concern for developing a globally effective 
vaccine against HIV. There are several candidate HIV vaccines employing different 
approaches, which are currently in development, either in clinical (human) trials or in 
preclinical development in non-human primates. 
It is generally accepted that an effective HIV vaccme will have to stimulate both 
neutralizing antibodies and cell-mediated immune responses in blood and at mucosal 
sites (McMichael, 2003; McMichael & Hanke, 2003). Most antibodies produced in 
response to HIV infection afford little if any control of viremia, appearing to select for 
virus escape mutants (Richman et al., 2003; Wei et al., 1995). However, passive 
immunization experiments have shown that neutralizing monoclonal antibodies can 
effectively protect from infection (Mascola et al., 2005b). Despite numerous approaches 
to elicit neutralizing antibodies (Calarota & Weiner, 2003) there is still no immunogen 
that can elicit neutralizing antibodies which are capable of effectively neutralizing 
primary isolates (Burton et al., 2004; Garber et al., 2004). If neutralizing, the antibodies 
require the induction of high titres difficult to achieve through vaccination (Mascola et 
al., 2005a; Mascola et al., 2005b). Due to difficulties in developing a vaccine that elicits 
neutralizing antibodies, the field has focused on vaccines aimed at eliciting T cell 
responses. 
A few promIsmg approaches capable of inducing high levels of circulating T cell 
responses have emerged, including vaccines based on Adenovirus 5 vectors, naked DNA, 
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disadvantage of T cell vaccines is that, they may not prevent the first wave of cell-free 
HIV from infecting host cells (Hanke, 2004). These vaccines may therefore primarily 
result in ameliorating disease, rather than preventing infection. 
There have been several approaches to design vaccine immunogens which are most likely 
to elicit cross-clade immune responses. One of these approaches is the development of 
vaccines based on a single HIV -1 subtype representative of the dominant virus circulating 
in a specific geographical region. Examples of this include the development of several A-
and C-subtype vaccines, as well as CRF _01 AE vaccine reagents (Graham et ai., 2006; 
Schultz & Bradac, 2001). The subtype C multigene SAA VI DNA-C vaccine, which 
expresses gag, RT, tat, nef and truncated env, selected vaccines genes from recently 
infected individuals based on closest to a South African consensus sequence (Burgers et 
ai., 2006). This vaccine is targeted to the southern Africa region where subtype C 
predominates. 
An alternative immunogen approach is based on phylogenetics, rather than using actual 
virus from within the population. In this approach, sequences are based on a consensus 
sequence or an ancestral sequence which will theoretically have more epitopes in 
common than an actual sequence. Such sequences have the advantage of being central 
and most similar to currently circulating strains of interest and may have enhanced 
potential for eliciting cross-reactive responses (Gaschenet ai., 2002). An example of 
such a vaccine is the clade B-based Adenovirus serotype 5 HIV -1 GagIPollNef vaccine 
. produced by Merck, currently being tested in adult South Africans. The vaccine is based 
on the subtype B CAM-l strain sequence. 
Another approach to developing a broadly cross-reactive vaccme is the multiclade 
approach, whereby constructs expressing HIV genes from different subtypes are 
combined. Using this approach, there is potential of individuals infected with different 
HIV -1 subtypes to recognize at least one of the immunogens used in the vaccine as it 
might correspond to the subtype with which they are infected. An example of the multi-
clade/subtype vaccines in Phase II studies is the DNA prime-Adenovirus 5 boost vaccine 
which expresses clade B gag, poi, nef, as well as clade A, B, and C env 
(http://Chi.ucsf.edu/vaccines/ vaccines? page=vc-Ol-0l). Positive results have been 
obtained during Phase I trials of this vaccine formulation (Graham et ai., 2006). The 
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responses than single subtype-based immunogens in rhesus macaques (Seaman et al., 
2005). 
Identification of only the immunogenic regions of the HIV proteome forms part of 
another approach of epitope-based vaccines in which CD8 epitopes are combined to form 
a vaccine. An example of this type of vaccine is the DNA- and Modified virus Ankara 
(MV A)-vectored candidate HIV vaccine expressing HIV-1 subtype A-derived p24/p17 
Gag fused to a string of HLA class I epitopes, the HIV A vaccine. This vaccine was 
targeted for East Africa as HIV -1 subtype A is the dominant circulating subtype in this 
region (Hanke et al., 2002). Poor immunogenicity of the vaccine however halted further 
clinical testing (Hanke et al., 2007). 
In order to be able to know which vaccine formulation works best, it will be necessary to 
perform vaccine efficacy trials. However, vaccine trials are lengthy, clues to whether 
immune responses generated will be cross-reactive can be obtained by testing for immune 
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1.7. Aim of the thesis 
South Africa is faced with an enonnous epidemic of HIV / AIDS and an effective vaccine 
is urgently needed to prevent new infections. HIV -1 is a highly variable virus and it is 
impractical to duplicate vaccine design efforts using country-specific strains for every 
nation and region that needs a vaccine. In addition, it is difficult to change the strains 
used during the long course of vaccine development, from initial concept to human trial. 
There are vaccines in advanced stages of development and testing that contain different 
HIV -1 subtypes. It is important to generate data that explores intra- and cross-clade T 
cell immune responses to vaccine immunogens included in vaccines. As host HLA 
background is inextricably linked to cross-clade recognition, it is important to perfonn 
these studies in a South African population since results cannot be extrapolated across 
populations. The data could then be used to assess the degree of cross-reactivity in a 
population where advanced phase vaccine trials are likely to take place in the future. 
The aim of the study reported in this thesis was to measure cross-clade immune responses 
to predict whether a vaccine based on one subtype will be effective in a population where 
a different subtype is circulating. To perfonn this study we obtained HIV-1 Gag 
peptides based on sequences currently included in vaccines, including a South African 
subtype C (strain Du422), a Chinese subtype C strain, the subtypes B CAM-1 strain 
sequence and sequences from subtypes A and D. The peptides were obtained from the 
International AIDS Vaccine Initiative (lAVI) (subtypes' A, Cs.A, CCH and D) and The 
National Institute of Health (NIH) Reference Reagent Repository (subtype B) and are 
current or potential future sequences included in candidate HIV vaccines 
1.7.1. Specific objectives 
1. To characterize the sequence of the infecting HIV -1 strain in HIV -1 infected 
subjects 
2. To detennine intra-clade HIV-specific T cell immune response using HIV 
Gag peptides based on HIV Gag immunogens currently incorporated in HIV-1 
subtype C vaccines, namely 
1. a Chinese subtype C isolate 
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3. To assess the degree of cross-clade HIV-specific T cell immune responses 
using peptides based on HIV Gag immunogens which are incorporated into 
vaccine candidates or may form part of future vaccine candidates, namely 
1. a subtype A sequence 
11. a subtype B sequence 
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2.1 INTRODUCTION 
2.1.1 HIV-l Gag as a vaccine immunogen 
The development of a safe, globally effective and affordable vaccine offers the best hope for 
the future control of the HIV pandemic. One of the major challenges in developing such a 
vaccine is the high degree of genetic diversity the virus exhibits. This high variation among 
gene sequences of HIV viruses belonging to different lineages is fuelled by high mutation, 
recombination and replication rates and driven by host immune pressures. The significance 
of HIV genetic variation in vaccine efficacy remains unresolved, but there is some indication 
that it might play an important role (Gaschen et ai., 2002). 
It is important for vaccine development, to know which regions of the viral genome, if 
targeted by the immune system, will result in the control of the disease. The best vaccine 
formulation should elicit both humoral and cell mediated immunity which is cross-reactive 
between the different HIV variants and subtypes. Studies have shown that preferential 
targeting of the HIV Gag protein is associated with better control of the virus (Masemola et 
ai., 2004; Zuniga et ai., 2006). A more recent study showed that broader Gag responses are 
associated with viral control (Geldmacher et ai., 2006; Kiepiela et ai., 2007). Gag is therefore 
an important region to include in candidate vaccines. In addition, Gag is important to studies 
investigating cross-clade responses as it is rich in T cell ,epitopes which are commonly 
targeted by the host cellular immune response (Addo et ai., 2003). 
HIV poi is the most conserved HIV gene (>90%) across HIV-I subtypes. Nef is also 
relatively conserved (80%) across subtypes A, B and C. However, env is more variable 
(>20%) even within a single subtype. HIV gag is relatively well conserved (85%) among 
subtypes A, B and C (http://hiv-web.lanl.gov).Itis divided into three main regions which 
encode three proteins, namely pI7, p24 and pI5. The p24 region of gag is highly conserved, 
while the pI7 and pI5 regions are more variable. This might be due to structural constraints, 
that is, mutations within the p24 might results in replicative defective or unfit viruses. 
However, there are well conserved motifs within the more variable pI5 region of gag. These 
conserved motifs are encompassing the V pr binding regions if HIV gag and are found in the 
p6 region of pI5. This nature of gag, containing both conserved and variable regions, will 
enable the comparison of cross-clade T cell mediated responses elicited by either variable or 
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responses, the conserved regions of the protein are expected to make a major contribution, 
since results from previous studies suggest that cross-reactive HIV -specific T cells recognize 
regions with lower entropy and higher inter-clade homology (Yu et ai., 2005). It is also 
important to know the kind of mutations leading to the abrogation of cross-reactive T cell 
recognition, hence the importance of having gene sequence data. 
Most T cell vaccines currently in development contain gag. Together, HIV -1 subtypes A, B, 
C and D account for approximately 72% of infections worldwide. It is therefore important to 
genetically characterize the HIV gag gene as it is contained in several vaccine immunogens 
to relate this sequence data with intra- and inter-clade T cell responses detected. 
2.1.2 Aim of the chapter 
This study aims to characterize HIV -1 gag sequences from subtype-C infected individuals 
from South Africa who will be investigated for cross-clade responses (chapter three). 
2.1.3 Specific objectives 
The specific objectives of this chapter are to 
1. Determine the sequence of the infecting virus and investigate the phylogenetic 
relatedness between study sequences and known sequences 
11. Compare the infecting viral sequences to the ELISpot peptide reagents used in cross-
clade immune study. The subtypes A, B, CS.A, CCH and D Gag peptides used to 
investigate immune responses are based on HIV isolate sequences included in current 
or planned HIV vaccine candidates. Peptides were provided by the International 
AIDS Vaccine Initiative, except for the subtype B CAM-l strain peptides which were 
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2.2 MATERIALS AND METHODS 
2.2.1 Characteristics of study subjects and sample collection 
Forty asymptomatic HIV infected individuals were recruited from each of the following sites: 
20 from the Perinatal HIV Research Unit at Chris Hani Baragwaneth Hospital, Soweto; and 
20 from clinics of the Desmond Tutu HIV Centre in Gugulethu, Cape Town. All participants 
signed an informed consent form prior to study enrolment. The University of Cape Town 
Research Ethics Committee approved the study protocol (Ref Number 21112004). The 
criteria for patient inclusion was a CD4 count> 350 cells/f.11 with no overt evidence or 
history of opportunistic infections. Sixty ml of blood were obtained from each individual by 
venipuncture in Acid-Citrate-Dextrose (ACD) tubes; Peripheral Blood mononuclear Cells 
(PBMCs) were isolated using standard Ficoll-Hypaque density gradient centrifugation and 
cryopreserved for immunological assays described in Chapter three. Plasma was also isolated 
from the gradient and stored at -70°C. A further 5 ml Ethylene-Diamine-Tetra-Acetic acid 
(EDTA) blood was obtained from the same individuals, plasma isolated and stored at -70°C 
for viral sequencing. 
2.2.2 RNA extraction 
The QIAamp® Viral RNA Mini Kit was used for RNA extraction (QIAamp® Viral RNA 
Mini Kit, QIAGEN, Valencia, CA). The sample is fIrst lysed under highly denaturing 
conditions to inactivate RNases and to ensure isolation of intact viral RNA. Buffering 
conditions are then adjusted to provide optimum binding of the RNA to the QIAamp 
membrane, and the sample is loaded onto the QIAamp spin column. The RNA binds to the 
membrane, and contaminants are washed away in two steps using two different buffers 
containing sodium azide and ethanol. In the fIrst step the column is centrifuged with buffer 
A WI and at 6000 x g (8000 rpm) for one minute, and then with the second wash buffer 
AW2, at 20 000 x g (14000 rpm) in a micro centrifuge (Eppendorf 22331, AG Hamberg, 
Germany). RNA is eluted by centrifugation at 6000x g (8000 rpm) in an RNase-free buffer. 
Plasma sample (140f.11) was used to extract RNA which was subsequently eluted in 60f.11 
RNase-free buffer according to manufacturer's instructions (Appendix AI). The RNA was 
either ali quoted into I0f.11 aliquots and stored at -80°C, or used directly for complementary 
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2.2.3 Full length gag cDNA synthesis 
HIV-I gag cDNA was generated using the Invitrogen Thennoscript™ RT-PCR System 
(Invitrogen, GmbH, Karlsruhe, Gennany). The system uses Thennoscript RT, an avian 
RNase H-minus reverse transcriptase enzyme to generate DNA using RNA as template. One 
micro litre of 10mM dNTP mixture (dATP, dTTP, dCTP and dGTP) and IJ-l1 (lOpmol, 2J-lM) 
of gag-specific primer, Gag D reverse (5' AAT TCC TCC TAT CAT TIT TGG 3') were 
mixed with 4J-l1 of HIV -I RNA and heated at 65°C for 5 minutes and then cooled on ice. The 
synthesis of cDNA was initiated by the addition of 4J-l1 of RT master mix (Table 2.1) and 
incubating at 55°C for one hour. The reaction was tenninated by heating at 85°C for 5 
minutes. RNA template was then removed by adding 0.5J-l1 of2U of E.coli RNase H supplied 
with the kit and incubating at 37°C for 20 minutes. All cDNA synthesis steps were carried 
out using the GeneAmp® PCR system (GeneAmp® PCR system 2700, Singapore). 
Table 2.1 cDNA synthesis reagents and volumes for RT PCR amplification 
cDNA synthesis reagent 




Distilled water (dH20) 
Total 







2.2.4 Polymerase chain reaction (PCR) and Agarose gel electrophoresis 
Nested polymerase chain reaction (PCR) was used to amplify gag sequences, whereby two 
sets of primers are used in two rounds of polymerase chain reactions with the second PCR 
product being shorter than the first one. This is perfonned to have shorter fragments for 
sequencing. 
2.2.4.1 First round PCR 
cDNA from the RT step was amplified in a first round PCR using gene-specific primers, Gag 
D forward 5' TCT CTA GCA GTG GCG CCC G 3' (HXB2 626-644) and Gag D reverse 5' 
AAT TCC TCC TAT CAT TIT TGG 3' (HXB2 2402-2382) where the numbers are the 
position of the nucleotide sequences of the primers relative to the HXB2 nucleotide sequence 
where the primers bind (Bredell et ai., 2007). The composition of the reaction and cycling 
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Primer gag D reverse 




















2.2.4.2 Second round Polymerase chain reaction 










2 minutes (940 C) 
1 minute (940 C) 
1 minute (550 C) 
1 minute (720 C) 
15 seconds (940 C) 
45 seconds (550 C) 
1 minute (720 C) 
7 minutes (720 C) 
Three gag regions (A, B and C) were amplified separately in a nested PCR. Five III of DNA 
from the first round PCR was added to a second round master mix, whose composition is 
shown in Table 2.4 below. The remainder of the first round product was stored at -200C. 
Primers used and their binding positions according to the HXB2 numbering positions were: 
A forward, 5' CTC TCG ACG CAG GAC TCG GCT T 3' HXB2 683-704; 
A reverse, 5' ACA TCG GTA TCA CIT CTG GGC T 3' HXB2 1303-1282; 
B forward, 5' CCA TAT CAC CTA GAA CTT TGA AT 3' HXB2 1226-1248; 
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C forward, 5' CCT TGT TOG TCC AAA ATG CGA 3' HXB2 1748-1768; 
C reverse, 5' TCT TCT AAT ACT GTA TCA TCT GC 3' HXB2 2356-2334. 
Table 2.4 PCR reagents and volumes for the 2nd round PCR amplification 
PCRreagent Fragment A 
lOx Buffer 5 
10mMMg 2 
10mMdNTPs 4 
Primer gag reverse 1 
Primer gag forward 1 
SuperTherm 0.125 
Distilled water 31.875 
cDNA template 5 
Total 50 




















2 minutes (940 C) 
1 minute (940 C) 
1 minute (550 C) 
1 minute (720 C) 
7 minutes (720 e) 
-END (40 C) 
Ten ~l of the second round peR was used for Agarose gel electrophoresis as described in the 
next section, and the remaining 40~1 was purified for sequencing using the peR product 
purification kit as described in section 2.2.5.1. 
2.2.4.3 Agarose gel electrophoresis 
The constant negative charge on nucleic acids allows them to be separated in an electric field 
in agarose gel electrophoresis based on their size. Agarose gel electrophoresis was used to 
visualize amplicons using horizontal gel electrophoresis apparatus (Stratagene, La Jolla, 
USA). A 1 % agarose gel was prepared by melting agarose powder (Agarose Di LE, 
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(10 mg/ml), a fluorescent dye used for staining nucleic acids was added to a final 
concentration of 5%. The gel was left for 30 minutes which was sufficient for it to cool and 
set, after which, it was submerged in 1 x TBE buffer before loading the samples into the 
wells. Ten III of DNA sample (pCR product) was mixed with 3111 (~16ng) of 0.25% 
bromophenol blue, an agarose gel electrophoresis loading dye that is used to track the 
migration of DNA fragments in an agarose gel, and then loaded into agarose gel wells. Three 
III of DNA molecular weight marker VI at a final concentration of 0.751lg shown in Figure 
AI, Appendix A4 (Roche, GmbH, Mannheim, Germany) diluted in 7111 of distilled water was 
loaded on the gel in order to determine the size and quantity of the PCR amplicons. The gel 
was run at 100 V for 60 minutes, sufficient for effective band separation. Visualization of 
DNA fragments was done using a UVP trans-illuminator (UVP, San Gabriel, California, 
USA) at 256 nm wavelength and then photographed with a Kodak ds ID Electrophoresis and 
Documentation Analysis System 120, v 2.0.3 computerized gel imager and software (Kodak 
ds ID digital science, v2.0.3). 
2.2.5 Purification and quantification of peR amplified gag molecules 
2.2.5.1 Purification 
The QIAquickR Spin Purification Procedure was used for the PCR product purification 
process (QIAquickR PCR purification Kit, QIAGEN, Valencia, CA). The process involves 
binding of DNA to the silica-gel membrane in the presence of a high salt concentration, 
followed by washing away of impurities using an ethanol containing buffer (buffer PE), and 
centrifugation and then elution of pure DNA with Tris-CI buffer (10mM, pH 8.5). Forty III of 
sample DNA were purified and eluted in 50111 of elution buffer according to manufacturer's 
instructions (Appendix A2). 
2.2.5.2 Quantification 
The DNA was quantified following loading of a known amount onto an Agarose gel and 
comparing the relative intensity to Molecular weight marker VI run in parallel. The 
concentration of each sample was determined by comparing the amplicon band intensity of 
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2.2.6 Sequencing 
The ABI PRISM® BigDye™ terminator V3.1 cycle sequencing Kit with AmpliTaq® DNA 
Polymerase FS (Applied Biosystems, Inc. Foster City, CA) and an automated ABI prism 
3100 genetic analyzer (Applied Biosystems, Inc.) was used for the sequencing reactions. 
Three overlapping fragments spanning full length gag were sequenced with gene fragment-
specific primers in both the forward and reverse directions using the di-deoxy chain 
termination method (Sanger et at., 1977). The standard di-deoxy chain termination method 
makes use of 2', 3' ddNTPs, which upon incorporation into the growing DNA strand by 
polymerases, results in chain termination. A ddNTP lacks a 3' -hydroxyl residue that is 
needed for phosphodiester bond formation between successive dNTPs. These ddNTPs are 
added to the reactions together with an abundance of dNTPs, resulting in competitive chain-
extension and termination. Oligonucleotide chains are produced with varying length, 
differing by single nucleotides. These are then fluorescently labelled, allowing for detection 
upon electrophoresis. 
A 15-20ng amount of purified amplicon DNA was added into PCR tubes. There were two 
tubes for each of the three gag fragments (A, B and C), one for the forward sequencing 
reaction and the other for the reverse sequencing reaction. One JlI of3.2 pmol of the forward 
and reverse primers were added into the appropriate tubes. The primers were the same 
primers as those used for the PCR reactions. The reaction volume was adjusted to 12JlI with 
diethypyrocarbonate (DEPC)-treated water, which inactivates RNases. Four JlI of 2.5 X 
sequencing buffer supplied with the kit (Appendix B3) was added and then 4JlI of sequencing 
enzyme mix from the BigDye™ terminator V3.1 cycle sequencing kit was added, giving a 
total sequencing reaction volume of 20Jll. The PCR cycling conditions are described in Table 
2.6. 
Table 2.6 Sequencing cycling conditions 
-- -----~~ ---- ----~-- - --- ----






_~ _____ , __ '_" __ ~ ________ 25 cycl~~ __ 
-END 
30 seconds (960 C) 
30 seconds (960 C) 
15 minute (500 C) 
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2.2.7 Sequence analysis 
The three gag overlapping fragments were assembled into a continuous full length gag 
nucleotide sequence using ChromasPro Version 1.34 (Technelysium Pty Ltd, USA). The 
sequences were aligned, using ClustalW for multiple alignments incorporated in BioEdit 
sequence alignment editor v7.0.5 (Tom Hall, Ibis Therapeutics; Carlsbad, CA) with 1000 
bootstraps. The alignment was manually edited and translated into amino acid sequences 
using BioEdit. The different gag regions were analyzed separately after alignment for 
contamination. Phylogenetic and molecular evolutionary analyses were performed using 
MEGA (Molecular Evolutionary Genetics Analysis) version 3.1 (Kumar, Tamura, Nei, 2004). 
For quality control and subtyping phylogenetic trees, the reference panel included sequences 
of different global HIV strains with respect to the full-length gag region of HIV -1, consisting 
of all subtypes (A-K) as well as circulating recombinant forms (CRFs) from the Los Alamos 
sequence database (http://www.hiv.lanl.gov/components/hiv-db/). Two sequences of each 
subtype and CRF were included, while subtype C reference sequences were considered as the 
majority of the panel since previous data showed that the majority of viruses circulating in 
South Africa are subtype C viruses. The chimpanzee SIV sequence was used as an outlier in 
all the phylogenetic trees. 
The Neighbor-Joining method with the Jukes and Cantor nucleotide substitution model 
(Jukes and Cantor, 1969) was used to determine the phylogenetic relatedness of the 
sequences. For the subtype C phylogenetic tree, subtype C gag sequences from different 
parts of the world were used as the reference sequences. 
REGA version 6.4.2 (de Oliviera et al., 2005) software was used for recombination analysis 
of the study sequences in four sequential steps. First a query (study subject's) sequence was 
aligned with 27 group M sequences A-D, F-H, J and K and a Neighbor-Joining phylogenetic 
tree was drawn. One hundred bootstrap replicates were used with 70% as the cut-off value. 
Secondly, the process was repeated with 28 CRF reference sequences in addition to 22 pure 
subtype reference sequences. In the third step, the query sequence was divided into small 
segments and a sliding window of 400 bp was moved along the sequence in 20 bp 
increments. Each segment in the query sequence and the reference alignment was then 
analysed for recombination using bootscanning methods, implemented in Phylogenetic 
Analysis Using Parsimony (PAUP). Finally, the alignments were examined to determine 
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likelihood mapping analysis implemented in the Treepuzzle software (Strimmer and von 
Haesler, 1997) and the results presented were as shown in Appendix B4, Figure B1. 
Genetic distance calculations were performed using the Poisson Correction (PC) distance 
model (Kumar and Nei, 2000). The model assumes equality of substitution rates among sites 
and equal amino acid frequencies while correcting for multiple substitutions at the same sites. 
Amino acid distances were calculated for full-length gag sequences between isolate 
sequences and peptide reagent sequences for subtype Cs (South African Du422 and Chinese 
C) and subtype B. For peptide reagents based on subtypes A and D, only p17p24 p2 distances 
were calculated because the peptides ranged encompassed these regions only. 
Shannon entropy, a measure of variability in an alignment that takes into account the possible 
amino acid substitutions at particular position as well as their frequencies, was calculated for 
aligned full-length Gag sequences from the study subjects. BioEdit (Biological sequence 
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2.3.2 Quality control of HIV -1 gag nucleotide sequences 
To ensure there was no PCR contamination or sample mix-ups, Neighbor-Joining 
phylogenetic trees were drawn for each gag fragment prior to sequence assembly. For the 
120 fragments analyzed in three separate phylogenetic trees, there was no evidence of 
unusually close clustering of sequencing confirming no contamination (Figure 2.2 a-c). 
There was evidence that the phylogenetic relatedness was preserved across all regions in four 
pairs of sequences (illustrated with a red arc). Fragments from a single individual had 
homologous overlapping regions of 70 bp further confirming these sequences came from this 
individual. Sequences from two participants (T-N 010 and M-T 009) showed relatively close 
relatedness on all the three separate phylogenetic trees (Figure 2.2 a-c) with relatively short 
branch length. Two additional sets of sequences CC22, CC04 and CCI7, and N-M20 and R-
L 12, also showed close relatedness in all the three trees. In all cases, the participants came 
from the same site and it is possible they are either a transmission pair, or they acquired 
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Chapter 2: Genetic characterization ofHIV-1 gag sequences 
2.3.4 Phylogenetic analysis 
2.3.4.1 Classification and phylogenetic relatedness of study sequences 
Complete gag sequences (1461-1515 bp) were generated from 40 subjects. All the study 
subjects' sequences clustered within subtype C sequences (Figure 2.3) using N-J 
phylogenetic trees. Four phylogenetic clusters (bootstrap values> 75%) were identified, 
three sequences from Western Cape Province (CC04, CC17 and CC22), and three pairs of 
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2.3.4.2 Recombination analysis 
Complete gag sequences were screened for recombination using a software program REGA 
version 2.0 (de Oliviera et ai., 2005). No recombination was detected for all 40 sequences, 
showing that they were all pure subtype C sequences within the gag gene (Appendix B4, 
Figure B 1). However, in four sequences some regions of the HIV -1 gag nucleotide sequences 
(CC01, CC04, N-S019 and R-M002) were found to be divergent from the typical subtype C 
sequence. 
2.3.4.3 Geographical clustering of subtype C sequences 
Comparison of sequences with other subtype C sequences from other parts of the world 
showed that Chinese, Brazilian and Indian subtype C gag sequences clustered together and 
separately from other subtype C sequences (Figure 2.4). Six subtype C clusters Du15l and 
Du422 (100%), M-T009 and T-N 010 (100%), T-M 016 and H-N 018 (97%), CC15 and 
CC20 (97%), CC04, CC17 and CC22 (99%) and N-M020 and ROL012 (100%) were 
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Chapt",r 2: G~nd;e eharacl",ri/ation 01" H1V-1 KaK sequences 
2.3.5 Characteri7.ation of tliffert'nlial const'rvation of IIIV -1 KUK region, 
10 characteriz", th", variability or tli ficr",nt {Jag protcin regions and the diff",r"'l11 <lfllino "cid 
chilllges in tm, diirer",nt r"'gions, Sh"nnon entropy and conscrvalioo plots "~r", pL'Tli>rlncd. 
Shannon ClllroP} is a measure of amino acid variability "t a giv~n JX"ilion thai takes into 
account bolh the number of JXlssiblc <Imino adds all(",,,,d a.nd lheir frcquency. As sllo"1) by 
otr..;,r studi",s, Cr<lg 1'24 had the 10"csl entrop} score, l'llllging from 0-1.25 ,,·hile as gag p17 
and p 15 had higher entropy scores ranging Ii-om 0-2.15 (Fig",e 2.5). 
\~y~~---y~~-~ .. y-) 
(l17 1)2-1 (l15 
Fi~lIre 2.5 Entrop: plms or isoblc seqlLCllc~s <leros~ th~ &lg r"'gion .. \lignm.111 
p::>sition is gi'en as amino "<ld ~'Osi{[on f\>< exarnpk alrgon,"r~ po!;ilion 1 C k' I ~() 
Scql1ences WL"" "lib'lll:<i with ih", South African subtype C Uu422 as the reference sequcnce 
(Figure 2.6). Other peptide reagL'llt sequenccs th<ll ar", lh", ('hin",s", C subtype~ R. A and [) 
were also included 10 "llow lilr comparison to isolate sequences as "ell. The p24 especially 
tr..;, m"jor homology region Wll, highly conserved "hen e01l1p<lrcd to otha Crag regions, 
I()ilowed b~' ih", P 17 r"'gion (Figure 2.6). The piS reglon WllS the Iellst well conserved region 
",·hen compared to other HIV (Ja.g rcgioll~. Htl\\ever, th~r", "~r", ~ome r~giOlls "ithin the piS 
thlll were relatively conserved. 
Figure 2.6 The pr",die\ed alignment of Til V-I gag amino acid sequences from South 
Alriean 111V-J strmns analyzed in thi~ study. Tbt multiple aligned "quen,es "her< compa('ed 
lo ELlSp'~ P"plidt "-"dg~nt ""qu~n"c, bo'«.'d {)" 'a<"i"~ <arxlidat~' (Sout~ African ,ubty"])<' C (Du422\ 
,ublyp" B, partiat Gag U)f ,uhtyp'" A and Dj. [I"" indicat~ amino a<id i<!<ontiti.,. whil~ th<> d,d"-,, 
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Chapter 2: Genetic Ch"racieruli lion of HIV- I gag ~eq uences 
2.3.6 (;cnetic distll ncc rcl~tiun shi p amung the m"jur H I V-I , u bty r cs 
In chapler three. we report OIl responses to HIV- l Gag ~ptide sequences based em flOIenti,,1 amI 
existing vaccine constructs which a~ subtype A (HIVA vaccine) (Mwau cr a/., 20(4), subtype, 
H CAM-l strain. D and h~o s.ubtyp~ Cs. one from Chinn (end and anoth~r on~ i'rom South 
Afri~" (CSA. tilt: tlu422 sequeoce induded in the SA'" VI subtype C vac<:inc). The genctic 
dist"nees Iletw~en theSt: pepti<le ",agents based on lh~ Gag prot~ins in these candidate vaccincs 
and in i'eeting ,iral ''-'<1u~oces were <letennined. Gendic distances lor South African C. Chine se C 
and sllbty~ B arc based on fulll~ngth Gag amino acid scqllencc,. whibt distances for subty~s 
II and]) arc based OIl gag 1'171'241'2 amino acid sequenccs as most of the 1'15 region is not 
contained in the vaccine constructs . %ldy subjects' sequences were more closely related 10 the 
CSA sequence with a median amino acid distancc of5,5~o (range 2-9"10 ). follo\\cd by the CC>1 
subtype C pept i d~ reagent with a median distance oj' 6% (ran~e 4-9%). Th~ medi"n amino acid 
distaoce between tile ,tudy ,ubj~ct '~queoces "nd the ,ubtypcs R pcptides was 12% (9-19"/.). A 
with a median di,tancc of 130/0 (range 11-20"10) and D with a median distance of II % (range 8-
18%. Figure 2.7). rhus. intra-subtype amino acid distaoccs were smallcr than inter-subtype 
~mino acid distances as expe<:ted. 
o,L-~ ____ ~ __ ~ ____ ~ ____ ~_ 
o 
./ 
Subtype of ELiSpOI p"pl;de 
Figure 2.7 /\mi"o Ac id distances between ,tudy subject sequences and ELlSpot 
peptide reagents. The range i. repTe>cTlIed by ,I>< ",h;"k.", J I>< loweT "rKl upper part of ,I>< box 













In thi. study. lhe ~ntir~ g<.I1( getlll ","'qucnc.:s and their prc:dickd r.nl~in transbt;ons from 40 mv-
I ,trains collocted fi'um tw" dim:r,n! rr('IVince' of ~:llAh Aliica. M.mciy WC'lCm Cafl<' and 
(jaut~ng. were genetically "har~,·t~nl~d. Phylogenetic analysis "I' th~ full length J!<lg g~ne 
cia>siflOd all th~ o;equcnces as pure IIIV-1 >uht}p" C "'qucnces. 'Ihi~ cl~'siflCati"n or the 
St'Ill./CtlC~' a<; subi}pc C viTl.lsc' further Surf,,,rI R'SuItS from pr~~iou~ Iin.JinJ1.S that the 
f'rcoommallt circulating IIIV-J ~i~ It' Suulh Africa 3re 'IIhtypc C "ru!oeS (~an Harmclcn ('I 
ul .• J o;,on; V3n fl3rmclcn ~"7 01_ I Q9Q). 
I'h~logcnctic an.::tly....s "I' HIV·I f1.Uf!. sc'lUCtlCC'< I"'o,id<: cI."..- ."idene.: ot the: @oogmphical 
chilltering "I' '''htypc C ,-irus.:s Iro n' Ind ia. Ik.uil and China. s.oulh African ~lll:n"'" "~r" 
di,tinct from Indian, Bruihan an.J Ch in= sequcnce, whil'h Ii,rmed mollOph)k:tic grnuf''<.. This 
is as a result offourockr cITc.t. in thc"" 1'I:gions a> the epidemics st~rtcd later. rhen" i, a di.crse 
epi.Jcmic in South Africa .• 1'K,wn t-y Ia"k "I' formalioo of monophrletil' group. This .how, 
multirk introdu"'i"", OrSUDI)pc C vinhcs in IOCo;c L'Oulltries. 
It i~ IInpu1l3ll1 I" as.. ... ·css Ih~ rC IJI~"'" ess of IIIV varianlS cin;uhuIIlS on a !'OPulHti"n and ~ac';ne 
.aI)Jid3!cs .. 'hich n:I)' be 1""lcd i ... lhal populalion 1(l lh,~ ,1ud). Ihe dilfert'llccs III It..: amino :reid 
dist.,nccs t>.:t\o.ec:ro studr 'lIllIypc C full-Icnb'lh ("'I! ""lu.,nc"" ~nd FI ISp"t I"P,,,k >equcnccs 
WlTC dcterm;,,<'(1. Th~ JX1lli,Jc re3b~nh iQ,- 100 ELiSpot assay~ (r~'JlOrI~.J in chaptCl' thro:) are 
I:>ascd 011 vaccine candidales from mil foor major IIIV-I subt}pcs IA. 1.1, t' ~"d I»). On 3'C'f"age. 
thc sUidy scqucoces were mo SI ~Iose l > rclmcd to the CSA (South Afri~un llu422) ""quell"'" 
included ill the SAAVI vaccine (Burgers CI 0/" 20(6), ""itlt a proteio di~tJnce of 55°,. (rangc 2-
9"1.). Th" amino acid di'ltan<.'c from Ihe (('I! «(,hioco;c) 'ublypc (' 'cc,ucr'K.·c .. a> 'imilar, "ilh a 
I"'ultin di'<lanl'r of 6% (raage 4-9" ,,). Amino acid dislan<:c~ "ere Ingher hel WCoIn >Hid) o;cqUCIlce, 
lind Ihe SUN )P" A scqu..",,, mdu.Jcd m Ihe HIVA ~accine (i\1\o.JU ,./ ,,/.. 20().4), r~. (range 9-
11 %). 8 included in the \ ·1"" .. ],. .. arclI": I"'hi~,-",. 2003), and I} ""'Il./Cnct:S, n o .. fr.IIlI.'!C I 1-2()'\;,) 
and I I",. (8-18%) r...'Sfl'XI ,~el). Ch;lp:cr thn.'(' ... ill in~<!'.lig.lIc ",h':locr Ih,,'SC .JilTco.'I'ICt.'S are 











Chapter 2: Genetic characterization ofmV-l gag sequences 
The sequences in the study represent a discrete region (gag), which encompasses approximately 
15% of the HIV viral genome. The segment length has relatively conserved regions mainly 
within p24. The p 17 region was more variable, with the p 15 being the most variable region of 
HIV gag sequences. The p 15 region is made up of various protein subunits namely pI, p2, p7 
and p6. Within p15, two highly conserved regions occur in the p6 domain. These regions contain 
the Vpr binding motifs. Previous studies have shown cross-clade responses are more commonly 
detected in epitopes located in conserved regions (Yu et aZ., 2005). Differences in diversity 
across the Gag region will enable this aspect to be explored further with respect to cross-clade 
responses in subtype C infected individuals. 
These data on full-length gag gene sequences of HIV -1 subtype C strains from the Western Cape 
and Gauteng provinces of South Africa confirm the dominance of HIV -1 subtype C viruses in 
South Africa. The differences in diversity across gag will enable us to differentiate the impact of 
diversity of different proteins encoded by the gag gene on cross-reactive immune responses. The 
data generated from this study provides the basis for the investigation of cross-clade immunity, 
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3.1 INTRODUCTION 
3.1.1 Intra- and inter-clade HIV -specific T cell responses 
The development of an antibody-based preventive HIV vaccine has been hampered by 
antigen-specific responses that have been strain-specific and generally unable to 
neutralize primary isolates (Coeffier et ai., 1997; Li et ai., 2005). Therefore, there has 
been increased interest in the induction of HIV -specific T cell responses in current 
vaccine approaches. However, one of the major obstacles in HIV vaccine development 
is the enormous genetic diversity of the virus, which also poses a problem in 
determining which immunogens to include in a vaccine. 
Among all HIV proteins, Pol is the most conserved (>90%) across all HIV -1 subtypes 
and is approximately 850 amino acids long. HIV Nef has a conserved central region 
and a variable outer region. Overall, Nef is also relatively well conserved (80%) 
across subtypes A, B and C. Gag contains both conserved and variable regions and 
overall, it is relatively well conserved as well (85%) across subtypes A, B and C. In 
contrast, Env is less well-conserved «80%) even within a single subtype (http://hiv-
web.lanl.gov). HIV Gag forms part of many current HIV vaccine candidates. It is 
included in a South African AIDS Vaccine Initiative (SAA VI) DNA vaccine (Burgers 
et ai., 2006). The gag sequence included in this vaccine was selected based on near 
consensus subtype C sequence, which is the Du422 sequence (Williamson et ai., 
2003). HIV Gag also forms part of the trivalent mixture of Adenovirus serotype 5 
vectors each encoding subtype B based Gag, Pol and Nef (Shiver and Emini, 2004). 
HIVA, a DNA- and modified virus Ankara (MV A) - vectored candidate HIV vaccine 
also express the p24/p 17 Gag coupled to CD8+ T cell epitopes (Hanke et ai., 2002). 
The level of sequence conservation for this protein coupled with its relatively large 
size (approximately 500 amino acids) suggests the existence of multiple T cell 
epitopes that are common to diverse viruses. Studies have found that lIIV -infected 
individuals mount robust T cell responses to HIV Gag protein (Addo et ai., 2003; 
Masemola et ai., 2004; Kiepiela et ai., 2004). Therefore, it is important to test for 
cross-reactive immune responses among HIV variants to the Gag protein based on 
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High frequencies of cross-reactive HIV -specific T cells have been detected by early 
studies (Cao et aI., 2000; Ferrari et al., 1997, Fukada et al., 2002). More recent studies 
have shown substantial cross-recognition of the major HIV -1 subtypes but with 
preferential targeting of the infecting subtype (McKinnon et al., 2005). Furthermore, 
these responses were shown to be substantial for the Gag protein particularly those 
regions with lower entropy and higher interclade homology (Coplan et al., 2005; 
Gupta et al., 2006; Yu et al., 2005). Generating further information on cross-clade 
HIV -specific T cell responses is important in HIV vaccine development strategies. 
South Africa is faced with an enormous HIV / AIDS epidemic and a successful vaccine 
is urgently needed to prevent new infections. It is understood that International AIDS 
Vaccine Initiative (lA VI) and the South African AIDS Vaccine Initiative (SAA VI) 
would like to implement phase III vaccine trials in South Africa with vaccine 
candidates that have been tested in phase 1111 trials within and outside of South Africa. 
Most notably, the Merck vaccine containing subtype B CAM-l strain gag currently in 
phase II trials in South Africa, is a possible candidate for further testing in South 
Africa, as well as clade C candidates from China. It is thus important to generate data 
that explores intra- and inter-clade T cell activity in subtype C-infected individuals in 
South Africa with clade A, B, C and D reagents that correspond to existing vaccine 
constructs. Also linked with cross-clade recognition is the influence of diverse HLA 
backgrounds, and it is important to measure the degree of cross-reactive T cell 
responses in a South African genetic background. The data can then be used to assess 
the degree of cross-clade reactivity in a population that represents future cohorts for 
Phase III vaccine trials. 
3.1.2 Aim of the chapter 
The aim of this chapter was to investigate intra- and inter-clade Gag-specific T cell 
responses in HIV -1 subtype C-infected individuals from South Africa. The subtypes 
A, B, CS.A , CCH and D Gag peptides used to investigate immune responses are based 
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3.1.3 Specific objectives 
The specific objectives of the work were 
i. To screen for intra-clade HIV-specific T cell responses using peptide pools in 
an ELISpot assay in 40 HIV -I subtype C-infected individuals, using Gag 
peptides based on vaccine constructs from a South African subtype C isolate 
(strain Du422), CS.A, and a Chinese subtype C isolate, CCH. 
ll. To determine cross-clade HIV-specific T cell responses using Gag peptides 
based on subtypes A (included in the HIV A vaccine), B (the CAM-I strain 
included in the Merck vaccine) and D. 
lll. To investigate the relationship between immune responses detected and 
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3.2 MATERIALS AND METHODS 
3.2.1 Peripheral Blood Mononuclear Cells (PBMCs) isolation 
During PBMC isolation, heparinized whole blood is layered on top of a density 
gradient material (FicolllHypaque) and subjected to a centrifugal force. The 
centrifugation process results in the blood tube contents dividing into four distinct 
layers, first the red cells, granulocytes and the dense solution at the bottom ofthe tube, 
second the separating disc separating RBC from PBMC, third the Ficoll layer 
containing PBMCs and lastly plasma layer. He top plasma layer is pipetted and the 
PBMC layer carefully transferred to a tube for further processing. 
Peripheral blood mononuclear cells (PBMCs) were isolated from freshly 
anticoagulated blood from 40 study participants in acid citrate dextrose (ACD) 
vacutainers, using standard Ficoll-Hypaque (Sigma-Aldrich, UK) density gradient 
centrifugation. Leucosep separation tubes (Greiner bio-one, USA) were used. The 
Ficoll was allowed to reach room temperature and 15ml was pipetted into 50ml 
Leucosep tubes. This was centrifuged for one minute at 1000xg (2300rpm in a 
Heraeus l.OR centrifuge). The blood in the vacutainers was mixed and 30ml poured 
onto the separating disc. This was centrifuged for 15 minutes at 1000xg as before. The 
top layer of plasma was removed without disturbing the PBMC layer. Plasma was 
stored at -80°C in cryovials. The PBMC layer was carefully transferred to a 50ml 
falcon tube, diluted to 50ml using PBS 1 % FCS (Invitrogen, USA) and centrifuged at 
250xg for 10 minutes. The supernatant was discarded and the pellet resuspended in 
5ml Phosphate Buffered Saline (PBS) 1 % Fetal Calf Serum (FCS). PBMCs were 
counted and stored at 10-20 x 106 per cryovial in 90% FCS 10% dimethyl sulphoxide 
(DMSO) and stored in liquid nitrogen. 
3.2.2 Cell counting 
Two methods were employed for cell counting. Manual cell counting was performed 
for the ELI Spot screening assays whilst the automated Guava cell counting procedure 
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3.2.2.1 Trypan blue counting 
The Trypan blue dye exclusion cell counting method is based on the principle that live 
cells have an intact cell membrane that excludes certain dyes such as Trypan blue, 
whereas dead cells do not. A cell suspension is simply mixed with a dye and visually 
examined to determine whether cells take up or exclude the dye (Strober, 1997). Cell 
suspension (15~1) for each sample was mixed with an equal volume (15~1) of Trypan 
blue (Sigma, USA) exclusion dye. The mixture was mounted onto a haemocytometer 
and visually examined and counted under a microscope (Olympus CX21FS1, 
Olympus, China) to determine the numbers of live and dead mononuclear cells. The 
chamber has a volume of 10-4 cm3 and total cell number per ml was obtained by 
assuming that lcm3 was equivalent to Iml and then multiplying the average of the top 
left and lower right quadrant cell numbers 104• 
3.2.2.2 Guava cell counting 
The assay principle is based on the different permeability of DNA-binding dyes that 
are fluorescently labelled. A first fluorochrome enters all cells and binds to DNA and 
fluoresces at its characteristic wavelength. A second fluorochrome enters only dead 
cells, binds to DNA and fluoresces at a different wavelength. Fluorescence intensities 
are then used to calculate the numbers of dead and live cells. A bead sample was 
prepared by diluting 20~1 of beads in 380~1 of diluent solution and acquired on the 
Guava PCA using the CytoSoftTM software in order to adjust the machine's settings. A 
1 :20 dilution of cells was prepared by diluting 1 O~l of cells in 190~1 of Guava Via 
Count Solution and left in the dark for 8 minutes. Samples were acquired on the 
Guava PCA using the CytOSoftTM software and total cell numbers and their viability 
determined (Guava Technologies, Inc, USA). 
3.2.3 ELlS pot assay 
The ELISpot assay is a simple and highly sensitive assay for the analysis of cytokine 
production at the single-cell level. It is particularly useful for analyzing specific 
immune responses to whole antigens or peptides. The assay is performed in 96-well 
microtiter polyvinyledene plates. In the first step, the wells are coated with high 
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(usually 100 OOO/well) and incubated for 18-24 hours in the presence of antigen. 
During this period antigen-specific responding cells release the cytokine, which is 
captured in the immediate vicinity of the cells. Cells are removed by washing and a 
biotinylated antibody directed to a second epitope on the cytokine is added. 
Streptavidin conjugated with HRP (horseradish peroxidase) is added. Finally, a 
precipitating substrate for HRP is added and the plates are incubated until spots 
emerge at the site of the responding cells (a period of several minutes). The spots are 
examined and counted using an ELISpot plate image analyzer with spot counting 
software. Calculating the number of spots according to the number of cells added to 
each well gives the frequency of the responding cells. 
3.2.3.1 Peptides 
The peptide sets used in the cross-clade study belong to Gag subtypes A, D, consensus 
B, CSA (strain Du422) and CCH (from China). Subtype B peptides were provided by 
the National Institute of Health AIDS Research and Reagent Repository, while 
subtypes CS.A, CCH, A and D were provided by the International AIDS Vaccine 
Initiative. The two subtype Cs and subtype B peptides spanned the full length Gag 
protein while subtypes A and D covered the p17, p24 and p2 regions. A pool and 
matrix approach was used in which five pools were made up for each of the five 
peptide variants (Appendix C, Table Cl) and 24 matrix: pools were designed to include 
all the single Gag peptides, which make up the five different peptide variants 
(Appendix C, Table C2). The consensus Gag B peptides were available as Img 
lyophilized peptides while the other four peptide variants were supplied at 
500/lg/peptide. Single peptides from the five peptide variants were reconstituted to 
10/l1 aliquots of 10mg/ml as stocks and then further reconstituted to 30/lg/ml as 
peptide pools or individual peptides and stored at -80°C. The peptides were used at a 
final concentration of 1.5/lg/ml in the ELISpot assay. CEF peptide pool was used as a 
positive control on all tested PBMCs. The CEF peptide pool constituted a panel of 32 
8-11-mer CMV, EBV and Flu virus peptide epitopes recognized by CD8+ T cells. The 
pool was reconstituted at 20/lg/ml in 90% PBS/lO% DMSO and stored at -80°C. An 
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3.2.3.2 Thawing of PBMCs 
PBMC vials were removed from liquid nitrogen storage and placed on dry ice while 
waiting to be thawed. The vials were thawed rapidly in a water bath at 37°C. The cells 
were immediately added to a 50ml falcon tube and 10ml of Roswell Park Memorial 
Institute (RPMI) with 10% Fetal Calf Serum (FCS) (RIO) media was added drop wise 
whilst swirling the cells. RIO was added to the cells up to 25ml and they were 
centrifuged at 250 x g (relative centrifugal force-g) for 10 minutes. The supernatant 
was discarded and the pellet was resuspended in 500111 of freshly prepared 
deoxyribonuclease (DNAse, O.2mg/ml) solution (prepared as I in 10 dilution with RIO 
media) and left for 2 minutes. RIO was added to the resuspended cells up to 25ml and 
cells were again centrifuged for 10 minutes at 250 x g. The supernatant was discarded 
and the pellet resuspended in 5ml of R20 (RPMI with 20% FCS) media. The cells 
were incubated at 37°C, 5% CO2 in an incubator (Thermo Electron Corporation, USA) 
with the caps slightly loosened. 
3.2.3.3 Plate coating 
Each well of a 96-well polyvinyledene plates (Microsep Millipore Products, France) 
was coated with 50111 of 5mg/ml capturing antibody, mAb I-DI-K (MabTech, 
Sweden). The coated plates were gently tapped to ensure that the entire membrane 
surface was completely covered with the coating monoclonal antibody. The plates 
were sealed with self adhesive plate seal (Brand products, Denmark) and incubated 
overnight at 4°C. 
3.2.3.4 Cell stimulation 
On the following day, the coated plates were washed three times with 200lli/well of 
sterile PBS in a Biosafety class II hood. Each plate was blocked with 1001l1/well of 
complete RIO media and incubated at room temperature for at least 2 hours. 
The PBMC samples were removed from the 5% C02 incubator and washed with 25m I 
of RI 0 and centrifuged at 250 x g for 10 minutes. The cell pellet was resuspended in 
5ml of RIO and counted as described in section 3.2.2.1 RIO was added to the cells up 
to 25ml and centrifuged as before. The supernatant was discarded and the cells were 
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The blocking RIO media was discarded from the plates without drying the plates 
completely. Fifty microlitres of peptide pools described in section 2.3.3.1 were added 
into each well at a final concentration of 1.51lg/ml. The peptide pools were added in 
duplicate, as well as 24 different matrix pools (Appendix C, Table C2) as shown in the 
plate layout in Appendix C, Table C3. Fifty microlitres of 8-11-mer CEF (BD 
Biosciences, USA) peptide pool (described in section 3.2.3.7) was added at a final 
concentration of 1.5ug/ml, and 50111 of Phytohaemagglutinin (BD Biosciences, USA), 
a non-specific stimulator was added last to avoid contamination. The cells were added 
last and were stimulated overnight for 18 hours in a humanized 5% CO2 incubator at 
37°C. 
3.2.3.5 Membrane development 
The following day, the plates were removed from the incubator and washed six times 
with 200IlI/well of PBS containing 0.05% Tween 20 (pBS-Tween) (Sigma, USA) 
using a plate washer (ELx50 Auto Strip Washer, Bio-Tek Instruments, USA). Excess 
fluid was removed by tapping on an absorbent towel. Fifty microlitres per well of 
biotinylated anti-human IFN-y monoclonal antibody clone 7-B6-1 (mAb7-B6-1, 
MabTech Sweden), diluted to 21lg/ml in PBS-lO% FCS was added. The plates were 
incubated for 3 hours at room temperature. 
Two hundred microlitres per well of PBS 0.05% Tween was used to wash the plates 
six times and Streptavidin-Horse-Radish Peroxidase (HRP) (BD Pharmingen, Canada) 
at I :500 with PBS-IO% FCS was added. This was incubated at room temperature for 
an hour. The plates were washed again six times with 200Ill/well of PBS-Tween. The 
membranes of the wells were developed with 1001ll/well of Nova Red substrate 
(Vector Laboratories, CA) for six minutes in the dark. The reaction was stopped by 
emptying the wells and rinsing in cold tap water. 
The number of cells producing IFN-y was counted for each well using an ELISpot 
plate reader (CTL Analyzer, CTL Technologies, Cleveland, OH) and expressed as 
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Peptides in pools and matrix pools that gave positive responses in the ELlS pot 
screening assays were tested individually to determine the reactive peptide in IFN-y 
ELlS pot assay. These peptide confirmation assays were performed on two selected 
individuals chosen because of their broad predicted reactivity. 
3.2.3.6. Test acceptance criteria 
A response was considered positive if the SFU/I06 PBMC exceeded 100 after 
background subtraction. An assay passed if there were less than 5 spots in each of the 
media control wells, not more than 100 spots in each of the media and cells wells and 
ifnot less than 400 spots were present in the PHA positive control wells. Details of the 
assay controls and test acceptance criteria are presented in Appendix C. 
3.2.3.7 ELISpot controls 
As progress is made towards developing a safe and effective HIV -I vaccine, there 
must be an assay that is robust and sensitive and the ELlS pot assay is one such assay 
(Mashishi and Gray, 2002). However, the reagents that can be used as positive control 
must be optimized and standardized. Although mitogens such as PHA provide a 
quantitative answer to whether the assay works, they do not test antigen-specific T cell 
stimulation. The use of the same antigen-specific stimulation in different assays rather 
than mitogen stimulation is also useful for standardizing the IFN-y assay as well as to 
monitor inter- and intra- assay variability. 
Antigen-specific stimulation in the current study was performed by testing study 
individuals for their ability to recognize peptides based on CEF, which are 8-12 amino 
acid long peptides arranged into 32 pools with sequences derived from 
Cytomegalovirus, Epstein - Barr virus and influenza virus. CEF peptides can be used 
for the stimulation of IFN-y release from CDS+ T cells in individuals with defined 
HLA types that have been exposed to the viruses. It covers 15 different HLA class I 
alleles, in particular HLA AI, A2, A0201, A3, All, A24, A68, A60SI, B7, B8, BIS, 
B27, B35, B44, B0702 (Currier et ai., 2002). 
The negative control wells consisted of six unstimulated PBMC and two unstimulated 
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(media only). Positive control wells consisted of two PHA-stimulated PBMC and two 
PHA-stimulated wells for the QC sample per plate. The control wells consisted of two 
CEF stimulated PBMC and two CEF-stimulated QC sample on each plate. 
3.2.4 Analysis of immunodominant peptides 
Reactive peptides that had> 1 000 SFU/I06 PBMC were cla~sified as immunodominant 
peptides. These peptides were analyzed for previously defined epitopes using the 
Epitope Location Finder tool at the Los Alamos immunology database 
(http://www.hiv.lanl.gov/contentlhiv-db/ELF /epitope analyzer.html). The tool looks 
for probable epitopes using previously defined epitopes on the database based on the 
submitted HLA type. 
3.2.5 Calculation of peptide variability 
Shannon entropy is a measure of the amino acid variability at a given position that 
takes into account both the number of possible amino acids allowed and their 
frequency. Entropy in each amino acid position is calculated as -IPaalogPaa, where Paa 
is the proportion of each amino acid in the respective position. When only a minority 
of a peptide sequence had gaps in a position, the position was included and the gaps 
were treated as separate symbols. A Shannon entropy score was calculated for each 
amino acid position of 5 corresponding peptide sequences for the 32 peptides that 
were reactive in two individuals. An average entropy score for all positions in each of 
the reactive peptides was determined to provide a single value that characterizes the 
overall variation of each peptide. 
3.2.6 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Prism Software, San Diego, California USA, www.graphpad.com). All 
data were analyzed by use of non-parametric statistics. Wilcoxon-signed rank tests of 
the difference between medians were used for significant differences between clade-
specific responses. The non-parametric Mann-Whitney (also called the rank sum) test 
for un-matched pairs was used for comparison of entropy scores for different peptide 
categories. Correlations were determined using the non-parametric Spearman's 
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were log transformed and the non-parametric Spearman correlation performed. All 
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3.3 RESULTS 
Thirty-nine HIV -I-infected individuals were screened for HIV -I-specific T cell responses using 
a panel of 540 peptides spanning the complete HIV -1 Gag protein from five different HIV-I 
sequences, two of which were from the same subtype. The peptides in the pools and matrices that 
gave positive responses in the first screening ELlS pot assays were confirmed using a second 
confirmatory ELISpot assay. 
Table 3.1 Characteristics of study subjects* 
Study Age CD4 count Study Age CD4 count 
Individual (Years) (Cells/fll) Individual (Years) (Cells/fll) 
CCOI 28 360.0 C-KOOI 31 561.4 
CC04 28 474.0 R-MOO2 30 909.5 
CC05 32 610.0 S-TOO3 29 578.0 
CC06 22 956.0 F-MOO4 34 348.9 
CC07 28 355.0 T-MOO5 27 637.8 
CC08 33 752.0 N-MOO6 27 1321.4 
CC09 27 453.0 N-MOO7 35 1010.5 
CClO 24 590.0 B-NOO8 28 1437.5 
CC12 47 536.0 M-TOO9 33 605.9 
CC13 38 414.0 T-NOlO 34 428.5 
CC14 47 510.0 A-MOll 46 637.0 
CC15 27 452.0 R-L012 19 628.2 
CC16 25 590.0 N-M013 28 573.6 
CC17 40 884.0 TSM014 26 295.6 
CC18 27 350.0 M-M015 23 502.0 
CC19 23 569.0 T-M016 29 702.6 
CC20 . 31 388.0 E-R017 35 999.2 
CC2l 46 347.0 H-N018 29 471.5 
CC22 31 420.0 N-S019 34 1167.8 
CC23 31 465.0 N-M020 19 554.3 
* All study subjects were heterosexual Xhosa people. They were all ARV-naive at enrolment. The median age was 
28 years (ranging 22-47 years). The median CD4 count was 492 cells/Ill (range 295-1437.5 cellS/ill). 
Study individuals were recruited from two provinces of South Africa, namely the Gauteng and 
Western Cape provinces. The majority of the individuals were all Xhosa people. 15/40 
individuals had CD4 counts below 500 cells/JlI and only 3/40 individuals had CD4 counts above 
1000 cells/JlI (Table 3.1). However, all the study volunteers were not on antiretroviral (ARV) 
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Figure 3.2 Levy-Jennings plot of quality control sample (NICD 063) T cell responses against CEF peptides. The middle dotted line represents the 
mean of the responses and the two lower and upper dotted lines represent the mean ± 2 SD. The assays are represented by the initials of the operator, followed by the date 











Chapter J: InTra- and CrQSS«: lade T cell imm~ne resptJllSe-' to Gag 
11Iin~ -1lI1le Sl:Udy in .. hvicu"l~ "..,.., ,scrc."ned I .... HIV-~l'cc l tic T c~ 1I responses 
againsT HI V lO/Ig ~plides arranged in rool~ ~",J matri, PI",1s. The tota1 
lnag,o.itu.ks of "">pO<1>'t: "cn: dt:tCffil iood Ii,r all pcphdc scts fOf I.'ad ~udy 
indi, idu:tl fnr t>cllh ",~,1 n:SPlm...::, and matrix responsc > I he rei:4,o,,-'-"ip 
bdw~en pool ,,,,p.:lI1'C, and matrix rcspoo,cs "'3, dctcm,incd lj~i n g Ih~ non-
paramdric Spearman mn]., currciation lUIal)',is.lor an EllSpot [lOOt matrix a,say 
to ),., MJcc~"liJl. re"P'I!\.'oCs in pools -;hould be au:omp3nied by rcspon'>Cs in a 
maici" containing at ka.st onc of lbe pcpt iOe~ fOlind in tbe PI~'I, This t."Ilab lcs 
reactive: pcplide:i 10 t'C iJ<. .. lilied. 1'001 unoJ mum~ " ::;PO ' Il'><ll> , hould therefOre 
b:l\c a positi~'c c"FI.'I:n ioo A5 Qlpn"\..u. main. n:'>fl''''.'Cs corre latcd Slnlllgjy 
" ith PlIOI n::;p '" "'" (P< 0,000 1. r - O.Q179. SPI'annan ran]., cm«:1ati"n) (figure 
3.4). '-" .. winll tbat pefllIJt.. .. Jet""I..u in the mauil< "co: pl"C>Cnt In tile pools \\ 1m 
posi(i,c rc>ponSCS. 
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Cha~tcr 3: Intr~ - ~nd CJ\lS,-ciad,,'1 ~d l immun~ re,>""",,,, to (jag 
Fi~u,,; ), S >ho",!; a .... '{'rCstflw.ti ~e El.ISpot a<;>ay plal~ fot" >tudy indi~i dual CC I Q. 
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Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
3.3.3 Cell-mediated immune responses to clades A, B, C and D 
3.3.3.1 Magnitude and breadth of HI V-specific T cell responses 
Individuals were examined for their T cell responses to five different HIV Gag 
peptides sets from four different subtypes, namely two subtype Cs, subtypes B, A 
and D using the IFN-'Y ELISpot assay. This was performed to investigate whether 
individuals can mount robust T cell responses to the Gag protein based on the 
different major HIV -1 subtypes. HIV -specific T cells were detectable in 97.4% 
(38/39) of the study individuals (Figure 3.6). The remaining individual (study 
individual A-M 011) did not have HIV-specific T cells recognizing anyone of 
the peptide pools tested using the IFN-'Y ELISpot assay. 100% (38/38) of the 
study subjects who had detectable IFN-'Y producing HIV-specific T cells 
recognized HIV -1 Gag peptides based on South African Du422 and Chinese 
subtype C peptide reagents (Figure 3.6). 
There was a wide range of HIV -specific T cell responses among different 
individuals. The magnitude of HIV -specific T cell responses ranged from 0-
19843 net SFU/I06 PBMC. There were 15 individuals who had cumulative 
responses >5 000 SFU/I06 PBMC, 11 individuals had 1 000-5 000 SFU/106 
PBMC and 12 had <1 000 SFU/l06 PBMC to CS.A Gag peptide pools (Figure 
3.6). A similar trend was observed for the CCH peptide pools, with 15 individuals 
had cumulative responses> 5 000 SFU/l06 PBM€, 14 individuals having 1000-5 
000 SFU/106 PBMC and nine having <1000 SFU/I06 PBMC to CCHGag peptide 
pools. For the remaining subtypes tested, there were fewer high magnitudes of 
responses. Subtype D peptide pools had the highest number of individuals with 











Ch"pl~'f J: Intra- ~ml "",><s-daJe T "ell immune resl"m~s tn Gag 
::::: L .. oM ! I ,' ~-',' 
h -. 
" ! ~ 
F • 
l ••... • 
• 
_ .... "..cu 
- ........ <:.,. 
_ "' .. "..11 - ..... , .. " 
•• ........ 0 
t ';g"re J. ~ J h~ 10iai magnitude of (jas rcsl'onso: to subtyp;s A. H. Cs ,. C(II and D r.,. "'P"""" ,"''''',. M, ,h. 'obi .'''11"'''''''' ~f II-"N.,{ proo"""g mv_ 
,,,",,n, I •• 11\ OJ do' .... '<J b) lh< H ISpu'-»'>olJ ..,,"'"~ 3') pwlidpant>. <_'PfC>M"J •• ,he """, .... ,of ,.., &rL 10" f' fI\ lr r,w III. diff=n, ","'~~ POP'"'" '",,\:0,,1< f ....... ch "nd) 











Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
The general trend of the magnitude T cell responses for the different subtypes was in 
the order CS.A, CCH, B, A and D. There were cases when CCH were higher than 
responses to Cs.A , for example T-M005, T-MOI6 and T-NOIO (Figure 3.6). In a 
single individual, there was strikingly high total magnitude of responses to non-
subtype C peptide pools when compared to subtype C peptide pools. This individual, 
N-M006, had stronger responses to subtype B-based peptide pools when compared 
to other subtypes (Figure 3.6). Individuals R-M002, CC012 and M-MOI5 had 
slightly higher magnitudes of responses to subtype B peptide pools when compared 
to subtype C peptide pools. There were no subtype A and D responses that were 
higher in magnitude than subtype C. 
There was high degree of recognition of the different subtypes. Thirty (78.9%) 
individuals recognized all five different peptide sets used (Figure 3.6). Three (7.9%) 
individuals recognized four peptide sets, and same applied to two peptide sets. Only 
two (5.3%) individuals recognized three different peptide sets. There were no 
individuals who recognized only one peptide set (Figure 3.6). 
The total magnitude of all pool responses to all the five peptide sets were compared 
for all the individuals using the non-parametric Wilcoxon signed rank test. This was 
performed in order to determine whether different peptide sets can elicit equal HIV-
specific T cell responses in HIV -1 subtype C-infected individuals. The median 
response to HIV subtype CS.A peptide pools for the study subjects was 2 530 (0-19 
817) SFU/l06 PBMC (Figure 3.7). This was slightly higher than the median 
response to the Chinese subtype C peptide pool reagents, at 2 470 (0-19 843) 
SFU/l 06 PBMC. However, HIV -specific T cells recognizing subtypes B, A and D 
peptide pool reagents had lower magnitudes of responses, namely 1 175 (0-17872) 
net SFU/l06 PBMC for subtype B, 868.3 (0-16723) net SFU/106 PBMC for subtype 
A and 560 (0-13 605) net SFU/106 PBMC for subtype D. In most cases, HIV-
specific T cells recognizing peptides based on the CSA and CCH gave the highest 
magnitude of responses. Thus, HIV -specific T cells recognizing peptides based on 
the heterelogous subtype, that is subtypes not responsible for infection, had lower 
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Chapter 3: lntra- and cross-clade T cell immune responses to Gag 
obtained are referred to as cross-clade reactivity ratios. Therefore, the ratio of 
subtype CS.A versus subtype CS.A is one, showing equal recognition of Gag peptides 
based on these HIV -1 variants by HIV -specific T cells. 
The mean ratio of HIV -specific T cell responses for all the 39 study subjects was 
1.08 (95% confidence interval [CI], 0.34-2.8) against subtype CS.A Gag versus 
subtype CCH Gag, showing that CCH had a slightly higher total magnitude of 
responses than CS.A• Ratios to other HIV -1 subtypes were lower than ratios within 
subtype Cs, showing that subtype C-infected individuals recognize peptides based 
on other subtypes with a lower magnitude than they do to clade-matched peptides. 
Ratios of 0.71 (95% CI, 0-2.48) were obtained against subtype B Gag, slightly 
higher than 0.51 previously described (Coplan et al., 2005). Ratios of 0.41 (95% CI, 
0-0.97) against subtype A Gag, is comparable to 0.47 previously described (Coplan 
et al., 2005), and 0.38 (95% CI, 0-1.05) against subtype D Gag were obtained. Thus, 
as expected, intra-clade reactivity ratios were higher than cross-clade reactivity 
ratios. 
Table 3.2 The ratios of cellular immune responses against the HIV -1 Gag protein 
for heterelogous versus homologous subtypes among 39 HIV -infected indiViduals 
Subtype comparison 
CS.A versus CCH 
CS.A versus B 
CS.A versus A 
CS.A versus D 
Previously reported for South Africa* 
A versus C 
B versus C 
*Coplan et ai., 2005 
Immune response ratio 

















Chapter 3: Intra_ and cross-clade 'I cell immune responses to Gag 
I'lre ~ro,"-reactivity of I HV -specific r cell, to the Cag: protein was i nve,ti gated in a 
more graphic "ay. Figure 3.8 ,fK"," Log, ~-tran,fonll ed ELI Spot III V -,!",ci Ii~ r cdl 
re'pon~,lS again,t tf>e Cag protein. rhe slope of the line of be,t fit i, approx imatd) 
1, making an angl" that is app"'>.imatd) 45° to th~ x-a.xi s. I his lin~ r~pre'''nts 
cross-clalk reactivity ratio of I 
Generally. there was a strong correlation of LoglO-!ranstormed ELlSpol respon s.es 
between the 'u bt) pe ('s,,' and the four other III V_I subtypes us.ed I I igure 3.R). Mo,1 
dala points clu'l~r around thi, line. illustrating this high degree of intra- and cm,,-
clade recognition. The highest correiation "a, ohtain..J I,ll' responses to the samC 
'ubtyp~. lretwe~n subtype Cs " and ,uhlyp" Cell (r - 0.9728, P < 0.0(01). wh~re 
most re~ponsC<. ciu,tcred closely around th~ 45" line (Figure 3.8). Subtype l \ A and 
D hall the lo""s! CroSS reactivity correiation Ir - 0.8595. P < 0.(001). "here it is 
clearl) sem that data point arc morc dispers.cd and funhcr away from thc 45 '; line. 
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Figu Fe J.7 Cross-reacti vily of 'r cell immune re'pon"" again,t III V-I Gag, V.ILI'" 
On the OXe' rer>""s,,~ tilt r"'t nt""bt, of IF"-r-exp,e" ir.g T «11./ 10" PH \1(, Il.,pon"", "i" 7HO 
oct WUII 0' PBMC, 'Hre a"ignod 0 v.lue of I. Tho r "Iu< i, the """-p",,m<lric ~pe,"'",.n 













The ~mino aciJ oJ ' ~ laJ1o(; e ""I ... ""n an )Jldi~iJ,,~r , inJ""ti ng ~ or~ 1 (jaJl prote in 
sequence and the pcpli d~ s~quence "er~ dctcrmincJ thi ~ " a, ploll~..J ~gau"'t the 
tOlal maj,,,,itud~ "f IFN-l' r~ .. p<..,"e to the parti~ubr p ~rt,dc \arlanl ,et on order 10 
oJdermine the' ,mfl llC l g..",ctic dist3lICc bas 011 tb~ recogniti"n "f (jag peptides be-
H1V·sfICCific 'I cc ll s. The!\: " as nil significam ~",.,-clati<)n 1>c'''CL'tltoc magnitude of 
rc;p0fls.: and gcoclk diSlarce hct"ecn the ' ''f''''ling ~ irJI ;<:\jucn,-c and tlK: LLlSpot 
f>CPlilk I'Cdgi:IU SC\Iu.:tICC (r -Q.tHJ1Z. p - 0 .% 70) (I"gul'l:: ] 9). 
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Figure 3.8 The relatiol1 ship t>ct\\CCll genetic diSl3ncc arrd 100al Illagnitude of 
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cell COUllt " a, d~ICrmtnL..J Ji,.. all ... ud~ f!"r1iclpanh ''''Ili Spearman corrdal ion 












Chapler 3: Intra- lind cr(»..~-dadc T cdl immune TC5po!lSCS (" Gal!! 
disease progoo,;",n. There \ \ 01$ a RCg>lli, ,, In:nd oblaillCtl ahl"",gh Ihis "as 001 
'l.:ui51icaUy \igml;.'lInl (r -0.074. p = o. 71-') (Figu~ 3, 10). 
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1\ ' 0 of lhe J'l stud) ~u"jech ,,~tt funhcr in" CSli~leJ fe>r the ir>J, ~idWlI po.lllidcs 
""fK.nsihk r,,, lhdr IIIV·specific 1'CSp<>1lSC'<. ~ [qltid, ... "crc predicted b) the 
1'",,1 ana rna!,;" ><.1ttni"g LU~pol attd oonlim'eJ in a ~uh~nl assa.) Ih'" tW() 
individuals C(,22 aod CC07 wen: eh""", hecau-.e " flOCil t>rortd preJictcd reHl1ivily. 
Due \0 time mnSll'llirll'. (ln ly Ihc,~ individuals· .ingle peptide rc'r"n'~' w~rc 
performed . 
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Chapter~' Intr~- a~ d cn."",·clcJd<: T cdl immu"~ r~spooSt!.~ tu Gal!. 
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Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
There were some reactive peptides which had the same sequence as the infecting 
viral sequence, for example peptides 19,48, 67 and 71. Peptides 3, 7 and 19 show 
the position of either HLA anchor residues or T cell receptor contact sites. These 
peptides had peptide variants that had single amino acid changes that lead to loss of 
recognition by HIV -specific T cells. Another category of peptides was those 
peptides which had amino acid sequences different from the infecting viral sequence 
but still had positive responses, for example peptides 115 and 118 (Table 3.3). This 
category constituted the majority of the peptides. These peptides might have their 
amino acid substitutions outside T cell receptor contact sites or HLA anchor 
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Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
For study subject CC07, a total of 15 peptides were recognized (Figure 3.12a). 
Peptide 72 was the most immunodominant and cross-reactive peptide for individual 
CC07, and together with other cross-reactive peptides, 37, 56 and 73, had high 
degrees of sequence similarity among their corresponding variants as well as to the 
infecting viral sequence (Figure 3.12a and Table 3.4). Subtype C peptides had the 
highest percentage recognition compared to heterelogous peptides (Figure 3.12b), 
with CCH again having higher recognition than CS.A• 
Peptide variants with similar sequence to the infecting viral sequence can be identified 
from Table 3.4. These are peptides 41, 56, 72, 73, 81 and 96. An interesting 
observation was the recognition of a peptide variant with a sequence different from 
the infecting viral sequence, while the corresponding peptide sequence with the same 
sequence as the infecting viral sequence was not recognized, as is the case for 
peptides 11 and 83. The subtype B variant of peptide 11 had positive response but its 
sequence differs from the infecting viral sequence while the two subtype C peptides 
had the same sequence as the infecting viral sequence, but were not recognized. For 
peptide 83, the CS.A had the same sequence as the infecting viral sequence but was not 
recognized, while the CCH peptide was reactive, but had a single amino acid change 
from the infecting viral sequence. This suggests escape from T cell immune 
responses. It is possible that the reactive peptide sequence is similar to the sequence 
which HIV -specific T cells initially encountered, which mutated to the current 
infecting viral sequence due to immune pressure. No HIV -specific T cells are present 
to the current epitope as it may no longer be able to bind the MHC molecule or TCR 
contact sites, however, a weak memory T cell responses still exists specific for the 
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Chapter 3: Intra- and cros~-clade T cell immune responses to (jag 
3.3A.2 Bread th of H I V -~pecilic T cell reo;ponse'> 
I he use of different pcptiocs sets to test for 'I cell immune responses was investigated to 
detennine whether extra responses cOlild be detected wtJ"n additional peptide variant sets 
are u,~d in an EIISpol ... "ay. the U'"' ofa numher "fpeptide sels il1~reased Ihe nurnher 
ofr~spnl1ses dek~kd. a, shown in Table 1.5 l'or l\HJ il1dividuals. The addition ora yariant 
subl}]>" C pepti& ""t is main I}' re,po.lll.,ible I'or this eIrecL Nn additional T cell response, 
were detected in these two ,tudy indi,iuudl, b}' the addition of sUblype D Gag peptides. 
Table 3.5 Peptide ,elS and number of response, detected 
Study Cu CS.A+C'1l CS.A+Cm+B CS,A+CCU+B+"- Cs,A+Cm+tl+,,-+f) 
Inui"iuual 
Ce22 14 19 19 20 1 " 
CCO, to 12 U [] 13 
3.3A.3 Distribution of T cell n'Sponses among IIIV-] Gag regions 
For each peptide set. a peptide with a different sequence from olhers ill the sume sel waS 
c"n~i&red a different pepli&. Aller mnsider-dli(Ml or commol1 ]>"ptides among th~ liye 
peptide varial1ls. tr..,r~ were 30 reactive peptide, recngl1iI.ed in the t\\O individual>. The 
distribution or the rcsponse, among the different Gag region, is shown in rable 3.6. 
Twenty percent (6130) of the peptides rcrognized were from the p 17 region, I he more 
conserved region of Gag, p24 contributed the majority of the peptides recognized (60"10. 
18130 peptides). Tbe last part of Gag protein (pIS). whieh is the mosl variable. 
contributed the same number of peptides as p 17 in these tv.'o individuals (20%, 6/30 
peplides), 
Table 3.6 I cell recognitiOil "f difTerent III V -I Gag protein reginns 
Protein No orpeptiocs O\emll ~'. recognition 
p17 6 20 
p24 '" 6<J p15 6 20 
Some peplKks had high magnitude of responses and a peptide \\htch had> I O()() SFlJII ()" 











Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
peptides were identified in the two study subjects, and the distribution of these within the 
Gag protein is shown in Figure 2.12. Two of the four peptides were from the p24 region. 
I 
RTLNA WVKVIEEKAF 





I pIS I 
Figure 3.12 The distribution of immunodominant epitopes over the HIV -1 Gag 
protein. Confirmatory ELISpot analysis was performed on two subjects to determine the reactive 
individual peptides. Shown is the distribution of immunodominant peptides found in two individuals 
as well as their sequences. Immunodominant peptides were defined as those peptides giving a net 
IFN-y ELISpot response of> 1000 SFU/I06 PBMC. The heights of the arrows are proportional to the 
magnitude of net IFN-y response to the peptide. 
The peptides which were classified as the immunodominant peptides in the two 
individuals were further analyzed for previously defined epitopes using the Epitope 
Location Finder tool of the Los Alamos Immunology Database (http://www.hiv.lanl.gov/ 
contentlhiv-db/ELF/epitope analyzer.html). These peptides had high epitope density and 
most of the epitopes were defined in individuals with known HLAs (Table 3.7). Peptides 
72 and 73 had the highest number of epitopes previously defined. The epitopic sequences 
common to peptides 72 and 73 were listed under peptide 72 and left out under peptide 73. 
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T .10'" J.7 ("'1)8' T L..,II .,.ilopes ";lhln Inlmunodonuu.1n1 pcpt;dc~ 
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Ch:lplcr 3: Irma- and cro.",-cjadt: r cdl imm~"" re'f,nn..es In Gd~ 
3JA.-I Variabi li.y of cross-ructi.e IIIV- I Ga~ 1K'l.lfda 
10 more clo>cly ci'arxlcria Ih" ~ ' I'lll "'giOf\~ IhM .... ~." p"'r.. .. ...nli~lI~ crO'\-f«"sni.red b~ 
HI V-I ·speciflC 1 cd1-.. "C da",ficd al1ln., 32 o\erb"ping !"'pt,,,,, -.cl, r'um Ih" , .... ~. c"nfirm<'<l 
whje~'s ~cwrding 10 n.~ogllilion o r Oll~. 1"0, throe. four or fiv~ p"ptidc varianlS. Illc mooian 
,hallllOll "nlropy "i-COI"CS of the pcplides in thcs.c two diflcfent groups "en: d~lerm incd (I igure 
3. 14 aj. Entl1'PY "alues rungeJ from 0-1 j 14 for alllhe pepllde SClS. I'eptidcs r"co\!.nized in one 
1>C<juence varianl (~ peptid~s) ",en: nl0re Ihan Ifmse recognized in ~ach of the ~. 3, 4 and 5 
St'"u.,ne" varian l~ O. () -I and 7, re.,po:~\h'cl)). 
The median Sh:mnon cnlrupy <.CO", o f "",plid..-;, .w:ogniztld in on., ~o.J ''''~, P'"Plidc ,arianh "as 
0.')..1 (range O.W· I.26) and 004-1 (.ange O.O~- I. SI), "'"",",,-'i,·ely. A~ ,""o"n in FigulC 1.14a. 
these I'C'P,idc 'ariallls h3d sisn1t1cantly hi~hcr ct\trop~ S<.:orcs "hen coml'ar.:d 10 (>Cptide 
variant" recognize<! in th ree, four ~lx! five sequcllce varianlS. "hose mooian ~hallJ>()n eml"Op) 
,em'", ""',,1"1: O. 1 9 (r~n\!.~ 0-0015). O.OR (range O. O~-O. 11 ) and 0.06 (rang~ 0.05-0.09). J"o:'pecli ve I) 
(I''';: 0.05, 'vIann-Whilney te'I). There WaS no signi fi cant difference ho:l"ecn In., enlrol') ,core 
01" peptide, remgnizW in on" ~"'Iucnc.: nriunl and Iho"! recol!\ni"",d In 1"0 st:'llk'nce \arianl, 
II' - 0.3<)69). Th~ ,arne wa~ In", li'f perli .... ' .""ognized in fnur "",uenee V"~rianl' and n,e 
SCf]UCJlCC ,anan!.> (p = 0.6551). 
Til<: flC:I"CCnl"SC' hQ....,I<~· for a!1 ,he Ii\c pcplido: ~ariams fanged from 5t16".o 1(1100" •. T he 
degru (If inl<;'f"-cla::ie homolc>gy. dcfillo.-d !lS Ihe tkgrcc of loCiIl.ICrKe ."'Il i lanl~ hctween llie 
ditlerenl cladc~ A B, C, A. C~"", and D """uence variant'. was hi!lhel,\ in the sub""t of pc{lIidc~ 
.t'Cngniz..:.1 in all fiv e ""'Iu~nc" ~arillnlS (Figure 3.14 h). P"ptidcs r.:cogn i:.tcd in Ihre". four and 
Ihe sequence I'ari :.m, had "ll:nifi~Jn\ly high~r p"rc~nla!,:~ humo"'!!Y "hen compared 10 
pcptidcs recognized in one and two "",uene.. ,arbnl~ (p<:0.05). There wJ, nu ~ignil1canl 
difference oct"ccn pcrcent:lgc homolof:) of pept;"", re~,,@;mred in (>I\~ and 1"0 St'qucncc 











Chaplet" 3: Intrn· alld cn)S;. .. d adc T cel l immw",' .C'f'l)lh ..... 10 (jill> 
" J p <eoo,~ 
,., p · O . m~1 
0 
" p - C-.0418 " " p' 0.3%0 '" , , "" .. , • • " .-




• , . 
3:2 ' . . " ,., 
~~ • , 
" I 
'. E ~ • -w , , , , 
Num~ .. . of HlV_1 s ub,we. 'ecognized 
, b) ____ .J' < 001~ 
'" 
• __ ~:. Q,0062 
~ ,....-- P. :.9.CJ(}42 
" ,,, p-07253 "" • . • , •• &, '.' 
0- • • 00 ~ .. " , g 
0 
" " , -, 00- .. • 0 , >: "." 
~l " 
! a .. , • , .. c , , , • , 
N~nbef of subt)pes leeOgnized 
. igun' 3. 13 Char(to;!~, i au ",n " I' ,;",1 I"' pl'des ",illl intra- and mtcH: l ... ,k nO!;s ""'<Ignition h~ 
HIV·sp<'<:irJ<: T cell s. (I ) S ig,nitkamly Iol " ~r \-"IuroP} or peptid<: . recognized in 3{ least lhr~~ 
subtype ,eq u,' ll cc •. (b) Significantl ) h i gh ~ r imer-c ladc homo],)!:!) Il l" J'l'plid~, r~c"gml~d in 
mor~ th an I w(] C lade-,[)CCific , cqucncc,. A ''''"~..., Shannon <!lImp)-5W,OS [oJ' pepli<l<> of lhe live d,il<rcnl 
HIV I'<pti<i< >ell ~~ I ~ I~c ELl S!"'t '''',''y ,It. ,""'"" 1'~Plhlt' " .... c ",",c!"'<,....,d ... oording to tho num l><r of ttl V 
) .ub,y"," n .. -II,oh nt h <of tilt ptplidc .. ~. "''''-'I'n","<I. Din",c'" <al<JP.'f'es ""<I'~ ""'np.or~d ~;i"ll lhe t.m· 











Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
3.4 DISCUSSION 
Immunogens designed to elicit T cell responses are the current focus in the development of HI V 
vaccines. Because of the significant sequence variation that exists between and within HIV-l 
subtypes (7-15% [Korber et al., 2001]), there is no agreement yet as to the importance of HI V 
subtypes and their impact on the immune response and subsequent efficacy of vaccines. 
The question of whether a vaccine based on one subtype can be effective in a population where 
a different subtype is circulating remains unanswered. Ultimately, the best way to have an 
answer to this question is carry out vaccine trials, but this is a very long process. Another way 
to approach this question is to carry out cross-clade studies in the laboratory. In this study, 
cross-clade immune responses were investigated in thirty-nine HIV -1 subtype C-infected 
volunteers. An IFN-y ELISpot assay was used using peptides based on vaccine candidates for 
subtype C (South African and Chinese), subtype B and subtypes A and D. A pool-matrix 
ELlS pot approach was used in order to identify the individual reactive peptides. The peptides in 
pools and matrices that gave a positive HIV -specific response were tested individually in a 
confirmatory ELlS pot assay for two highly reactive individuals. 
Initially, validation of the assay was performed. There was a significant correlation between the 
magnitude of responses obtained in pools and those obtained in matrices. The inclusion of a QC 
sample helped in determining which assays passed, as well as in monitoring inter- and intra-
assay variability. 
The total magnitude of IFN-y responses were not significantly different between peptides based 
on subtype C (South Africa and Chinese) peptides. These intra-clade responses were 
significantly higher than responses to other subtypes, namely subtypes B, A and D. These data 
suggest that even though subtype C-infected individuals mount robust IFN-y responses against 
different HIV subtypes, there is preferential recognition of peptides based on the infecting 
subtype. Previous studies have also found the same results (McKinnon et al., 2005; Yu et al., 
2005). Overall, there were substantial cross- and intra-clade HIV -specific T cell responses 
detected in this study. This is further supported by the high cross-clade reactivity ratios as well 












Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
Whether genetic distance between the infecting virus sequence and vaccine immunogen 
sequences has an impact on vaccine-induced immune response is important in vaccine design. 
In this study no correlation was obtained between the magnitude of HIV-specific IFN-y 
responses and overall amino acid distances between the infecting Gag sequence and Gag 
peptide reagent sequences. This might be due to the fact that genetic distances encompassed 
other regions not important in eliciting immune responses, and that those regions are outside the 
epitopic region of the peptides. 
An investigation of the distribution of the HIV -specific T cell immune responses across the Gag 
showed the p24 region contributes most of the responses. This is likely to be due to the fact that 
p24 is generally more conserved when compared to the p17 and pIS regions. This identification 
of the most immunogenic region of Gag is important in HIV vaccine immunogen selection 
since an ideal candidate vaccine will have to contain those regions of the HIV genome that can 
elicit strong T cell responses. However, there were some peptides from the p 17 and pIS regions 
of Gag which gave rise to cross-clade responses of high magnitudes. These peptides may not be 
ignored in vaccine immunogen design since they make an important contribution to the total 
Gag-specific T cell response. This identification of Gag p24 as the most immunodominant 
region of HI V proteome has also been found by other researchers (Yu et al., 2005). 
A detailed evaluation of cross- and intra-clade cellular immune responses to HIV -1 Gag was 
performed for two of the volunteers. In these individuals, the five peptide variant sequences 
w~re compared to the infecting virus sequence. Some peptides were not recognized at all. Some 
peptide variants were not recognized may be due to variation within the epitopic regions that 
resulted in loss of recognition by the restricting HLA or loss of recognition by T cell receptors. 
In other cases, an individual recognized some variants ofthe peptides sets tested and not others. 
This might be due to the fact that some mutations can not be tolerated by HLA molecules if 
they are non-conservative and involve HLA anchor residues. In addition, the amino acid 
changes might be involving HIV -specific TCR contact sites, leading to lack of recognition. 
However, there were cases where there was recognition even though corresponding peptides 
differed in their amino acid sequences. This suggest that TCR of mv -specific T cells can 
tolerate some degree of amino acid substitution, though analysis of these amino acid 











Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
being replaced by other amino acids of more or less the same charge, hydrophobicity and size). 
Another reason could be that the nature of amino acid substitutions could be tolerated by HLA 
anchor residues. 
There were cases where the peptide sequences less closely related to the infecting sequence 
gave rise to a positive response while as the one closest or similar to the infecting sequence was 
not recognized. This might suggest escape from the cellular immune response. Possibly the 
recognized sequence was present before the day of sequencing which mutated due to immune 
pressure, and the peptide sequences were similar to this sequence before mutation hence 
recognition by HIV -specific T cells. Therefore, HIV -specific T cells could still recognize this 
sequence which they encountered first. Overall, these data suggest that variation outside the 
HLA anchor residues and TCR contact sites might have less impact on vaccine induced T cell 
reactivity. Furthermore, HLA anchor residues and TCR contact sites can tolerate some degree 
of amino acid substitution. 
Results of the analysis of the breadth of responses from the individuals showed there was 
preferential recognition of peptides based on subtype C, as the individuals were infected with 
this subtype. The two individuals had broad HIV -specific T cell responses averaging 17 
peptides. Most of these peptides came from Gag p24 region. The recognition of more p24 
peptides than p 17 or pIS might suggest that mutations within this region that result in 
abrogation of T cell responses might be those that the virus cannot tolerate due to fitness cost 
on replicative capacity. This results in less variation in this region of the virus. This is inline 
with results from a previous study which showed fitness cost in mutation in Gag p24 epitope 
TSTLQEQIW (Martinez-Picado et al., 2006), which is found in peptide 58 recognized by 
individual CC22 with W replaced by A. The results on the breadth of the responses suggest that 
using different peptides sets in testing for HIV -specific T cell responses increases the breadth of 
detectable T cell responses as found in a previous study (Currier et al., 2006). However, the 
breadth ofthe responses did not significantly differ among the different subtypes. 
The most immunodominant peptide in the two individuals was peptide 72 (sequence 
KEPFRDYVDRFFKTL). This peptide has a high epitope density and has been identified 











Chapter 3: Intra- and cross-clade T cell immune responses to Gag 
restricted by different HLA molecules, thereby covering people with different HLA 
backgrounds (Frahm et al., 2007; Kiepiela et al., 2007; Masemola et al., 2004). 
Further characterization of the individual reactive peptides in two individuals allowed the 
classification of the T cell responses detected in this study into five categories, namely those 
recognizing one, two, three, four, and five peptide sets. The significant difference between 
those T cell responses recognizing at least three peptide variants and those recognizing one or 
two (the former being higher than the latter) suggest that cross-clade HIV -specific T cell 
responses are focused towards peptides with low intra-clade entropy and simultaneously high 
inter-clade homology. The data suggest that among the five Gag peptide variants used in the 
study, corresponding viral regions share a similar degree of viral diversity. This is probably due 
to structural constraints that prevent sequence mutations in specific parts the gag gene. 
In summary, cross-reactive HIV-specific T cells preferentially recognize peptides with low 
entropy and simultaneously high inter-clade homology. HIV-l SUbtype C-infected individuals 
can mount substantial cross- and intra-clade immune responses. However, there was no 
difference in immune reactivity between South African or Chinese subtype C Gag peptides, 
suggesting that vaccines based on these immunogens would work equally well. On the other 
hand, the magnitude of responses to other subtypes was lower, suggesting that vaccines based 











Chapter 4: Discussion and conclusion 
CHAPTER 4 
4.1. DISCUSSION AND CONCLUSION 
An effective HIV vaccine will need to protect against multiple HIV subtypes or recombinant 
forms. In the present study, full length gag sequences from forty HIV -infected volunteers were 
genetically characterized. Cellular immune responses in these individuals were assessed to 
determine their ability to recognise peptides from genetically diverse viral isolates representing 
multiple subtypes. The peptide reagents used in this study were based on five sequence variants 
representing four subtypes including South African subtype C (CS.A, strain Du422), Chinese 
subtype C strain (CCH), subtype B CAM-l strain, and subtypes A and D. The subtype CS.A and 
A sequences used in this study are based on immunogens expressed by candidate HIV vaccines 
which are in the process of going to clinical trial or have been tested in humans (Burgers et al., 
2006; Hanke et al., 2004). 
The individuals in this study were all infected with subtype C viruses. This is in line with 
previous studies, that have shown that the major circulating viruses in South Africa are subtype 
C viruses (van Harmelen et al., 1999). No recombination breakpoints were detected. This lack 
of recombination in these subtype C viruses should improve the prospects of vaccines based on 
subtype C gag sequences in that it is unlikely that they will fail due to the emergence of escape 
recombinants expressing vaccine targeted epitopes derived from non-subtype C viruses (Bredell 
et al., 2007). As shown with previous studies, there is clear evidence of geographical clustering 
of subtype C isolates from various parts of the world (Bredell et al., 2007), with Brazilian, 
Indian and Chinese sequences forming well-supported monophyletic groups in the gag subtype 
C phylogenetic tree. This indicated that these subtype C epidemic in different regions of the 
world are genetically distinct. Studies on subtype C sequences from China have shown that 
these viruses are BC recombinant viruses; however, their gag gene is derived from subtype C. 
Studies have shown that individuals can mount cross-reactive T cell responses (Cao et al., 
2000; Ferrari et al., 1997; Buseyne et al., 1998). However, many of these earlier cross-clade 
studies have focused on a limited number of selected epitopes. Moreover, the studies relied on 
the use of pools of overlapping peptides or cells infected with vaccinia virus constructs 
expressing the entire HIV proteins and therefore could not assess the degree of cross-clade 











Chapter 4: Discussion and conclusion 
1998, Currier et al., 2003). More recent studies have looked at cross-clade immune responses at 
the peptide level (Yu et al., 2005). However, sequence data was not generated in most of these 
recent studies to allow additional characterization of these cross-clade HIV -specific T cell 
responses. 
We have investigated T cell reactivity of 39 individuals whereby the sequence of the infecting 
virus is known. In addition, we have assessed responses against Gag peptides from five 
sequence variants, South African C, Chinese C, subtypes B, A and D at the single peptide level. 
Although South Africa and China have genetically distinct subtype C epidemics, in this study, 
the magnitude of HI V-specific T cell responses to Chinese and South African subtype C peptide 
variants did not significantly differ. However, the magnitude of the responses to these two 
subtypes C peptide variants was significantly higher than that of Gag peptide reagents based on 
subtypes B, A and D sequences. This is further corroboration of results from previous studies 
which have shown that HIV -specific T cells are cross-reactive among different HIV subtypes 
but with preference to the circulating subtype (McKinnon et al., 2005; Geldmacher et al., 
2007). The magnitude of response to the five peptide variants were in the order CCH> 
Cs.A>B>A>D. These data suggest that vaccines based on these HIV-l subtype C sequences 
(subtype-matched vaccines) may work equally well in HIV-l subtype C-infected individuals 
from different regions in the world. In addition, although vaccines based on other HIV subtypes 
may still induce cross-reactive responses, this reactivity may be less in subtype-mismatched 
vaccines. 
F"urther dissection of the CD8+ T-cell immune responses to the three individual Gag proteins 
showed the major contribution of Gag protein 24 (P24). This is likely to be due to the conserved 
nature of this region of the Gag protein. Interestingly, p 17 and p 15 had an important 
contribution to the responses and had regions that mounted cross-clade immune responses 
despite them being variable. It will be interesting to see whether these cross-clade responses 
relate to vaccine induced cross-clade immunity. 
The results from this study demonstrate that within a single study individual, some HIV 
peptides can be exclusively recognized in the clade C sequence variants (South African C and 
Chinese C) while others were uniquely recognized in the clade A, Band D peptide variants. 











Chapter 4: Discussion and conclusion 
of clade A, B and D peptide variants and not the corresponding clade C peptide variants is of 
importance in the study of HIV -I-specific T cell immune responses using the ELI Spot assay. 
This reflects that the use of different peptide variants increases the number of responses that can 
be detected compared to if only one peptide variant had been used. 
An important analysis for vaccine design is the relationship between the genetic distance of the 
infecting sequence and the peptide reagent sequences that were used in the ELI Spot assay and 
the magnitude of IFN-y response. Although there was a weak negative association between the 
magnitude of response and amino acid distances, there was no significant correlation between 
the two. However, HIV -specific T cells recognise epitopes, only very short protein regions. 
Amino acid distances used were for the full length Gag peptide sequences and included 
sequences outside of the epitopes. Variation in these less important regions might have affected 
the results. Therefore it was necessary to analyse individual peptide variants. 
Further characterization of peptides used in the study identified viral regions with low intra-
clade diversity and simultaneously high inter-clade homology that were preferentially 
recognized by T -cells among all the five peptide variant sequences. This analysis allowed the 
classification of all the individual reactive peptides in two individuals into five categories that is 
those that were recognized in one, two, three, four and five peptide variants. Indeed, those 
peptides that were recognized in three or more peptide variants had significantly lower entropy 
scores and simultaneously high percentage homology when compared to peptides recognized in 
one or two peptide variants. Overall, these data suggest that within the clade A, B, C and D 
sequences, some corresponding viral regions share a similar degree of viral diversity, possibly 
due to structural constraints that prevent sequence mutations in specific parts of the viral 
genome. Some of these cross-recognized peptides were identical across the five peptide variants 
and their cross-recognition was therefore evident. Yet, cross-clade recognition of peptides with 
considerable differences in their amino acid composition was also observed, where most of the 
amino acid changes were conserved or semi-conserved. In other words, an amino acid was 
replaced with one that falls in the same charge or hydrophobic category. This suggests that T 
cell receptors of HIV -specific T -cells as well as HLA molecules can tolerate some degree of 
amino acid substitution in their epitopes without total loss of epitope recognition or binding as 











Chapter 4: Discussion and conclusion 
The study presented in this thesis was limited in that only two individuals were investigated for 
the single reactive peptides responsible for the Gag responses. This was due to time constraints. 
Further work on the study will complete the identification of peptides predicted from the 
screening ELI Spot assay in the remaining 37 study individuals. This will allow for more depth 
analysis of breadth of responses to the different subtypes, as well as comparisons with the 
infecting viral subtype. 
This study only investigated the monofunctional aspect of the cellular immune response, 
namely the production of IFN-y. It will be interesting to determine the production of other 
cytokines such as TNF -u and functions such as cytotoxicity to see whether they have higher 
cross-reactivity than IFN-y production association with better clinical outcome. This is because 
the immune correlates of viral control are not yet clear, but recent studies suggest the 
importance of polyfunctional CD8+ T cells (Betts et al., 2006) and therefore, will be important 
to know whether polyfunctional HIV -specific CD8+ T cell are associated with higher cross-
reactivity. 
In conclusion, this study showed that subtype C infected individuals recognized peptides based 
on Chinese and South African sequences equally suggesting that it will not be necessary to 
design vaccines based on regional variation. In addition, while extensive cross-clade 
recognition was detected, the total magnitude of cross-reactive T cell responses was lower than 
that of intra-clade T cell responses suggesting that there are some advantages of matching a 
vaccine to circulating subtypes. However, the inclusion of new generation of vaccines that 
include immunogens such as T cell mosaic antigens that reduce the effect of diversity would 
potentially be beneficial to enhancing effective vaccine-induced cross-clade responses (Fischer 













Appendix A: Molecular Biology Techniques 
A1: RNA Extraction 
• Samples were equilibrated at room temperature (IS-20°C). 
• Buffer A VE was also equilibrated at room temperature for elution in step 10. 
• The precipitate in buffer A VL/Carrier RNA by heating, if necessary, and cool to 
room temperature before use. 
• All centrifugation steps were carried out at room temperature. 
1. 560~1 of prepared buffer A VL containing Carrier RNA was pipetted into 
a 1.5-ml micro centrifuge tube. 
2. 140~1 of plasma was added, mixed by pulse vortexing for 15 seconds. 
3. The mixture incubated at room temperature (IS-25°C) for 10 minutes. 
4. This was brief centrifuged to remove drops from the inside of the lid. 
5. 560~1 of 96-100 % ethanol was added to the tubes, pulse-vortexed for 15 
seconds and brief centrifuged. 
6. 630~1 of the resulting solution was applied to QIAamp spin column in a 
2ml collection tube without wetting the rim and centrifuged at 6000 x g; 
8000 rpm for 1 minute. The spin column was placed into a clean 2ml 
collection tube and tube containing the filtrate was discarded. 
7. The QIAamp spin column was carefully opened and step 6 repeated. 
8. 500~1 of buffer A WI was added and centrifugation performed at 6000 x 
g; 8000 rpm for 1 minute. The column was placed into another clean 2ml 
collection tube and the filtrate was discarded. 
9. 500~1 of buffer A W2 was added and centrifuged at full speed 20 OOOx g; 
14 000 rpm for 3 minutes. 
9a Spin column was placed into a clean 2ml collection tube and centrifuged 
at full speed for 1 minute. 
10. The QIAamp spin column was placed into a clean 1.5ml micro centrifuge 
tube and 60~1 of elution buffer A VE was added, incubated for 1 minute 













A2: peR purification of amplicons 
A protocol designed to purify single- or double-stranded DNA fragments from PCR and 
other enzymatic reactions. Fragments ranging from 100bp-lOkb are purified from 
primers, nucleotides, polymerases, and salts using QIAquick spin columns in a micro 
centrifuge. 
• Ethanol (96-100%) was added to buffer PE before use. 
• All centrifuge steps were carried at 13 000 rpm (~17 900 x g) in a conventional 
tabletop micro centrifuge. 
1 5 volumes (200111) of buffer PB was added to 1 volume (40111) of the PCR 
sample mix. 
2 A QIAquick spin column was placed in a provided 2 ml collection tube 
3 The sample was applied to the QIAquick column to bind DNA and spun for 60 
seconds. 
4 The flow through was discarded and the QIAquick column placed into the same 
tube. 
5 0.75 ml of buffer PE was added to the QIAquick column and centrifuged for 60 
seconds to wash. 
6 The flow through was discarded and the column placed back into the same tube. 
This was centrifuged for an additional 1 minute. 
7 The QIAquick column was placed into a clean 1.5 ml micro centrifuge tube. 
8 50111 of buffer EB (10mM Tris-Cl, pH 8.5) was added to the centre of the 
QIAquick membrane and centrifuged for I minute to elute DNA. 
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Table At Amino acid codes 
Amino acid 3-letter code IUD code Amino acid 3-letter code IUD code 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenyalanine Phe F 
Cystine Cys C Proline Pro P 
Glutamine Gln Q Serine Ser S 
Glutamic acid Glu E Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 













Table A2 Codons 
3-letter code Unambiguous codons IUBcodons 
Ala GCT, GCC, GCA, GCG GCX 
Asp, Asn GAT, GAC, AAT, AAC RAY 
Cys TGT, TGC TGY 
Asp GAT,GAC GAY 
Glu GAA,GAG GAR 
Phe TTT,TTC TTY 
Gly GGT, GGC, GGA, GGG GGX 
His CAT,CAC CAY 
Ile ATT, ATC, ATA ATH 
Lys AAA,AAG AAR 
Leu 
TTG, TTA, TTR 
CTT,CTC,CTA,CTG CTX 
Met ATG ATG 
Asn AAT,AAC AAY 
Pro CCT, CCC, CCA, CCG CCX 
GIn CAA,CAG CAR 




TCT, TCC, TCA, TCG, TCX 
AGT,AGC AGY 
Thr ACT, ACC, ACA, ACG ACX 
Val GTT,GTC,GTA,GTG GTX 
Trp TGG TGG 
XXX XXX 
Tyr TAT, TAC TAY 
Glu, Gin GAA, GAG, CAA, CAG SAR 














Appendix B: Molecular Biology Reagents and recipes 
BI: lOX TBE Buffer 
108g Tris-HCI 
SSg Boric acid 
20mll.SM EDTA 
made up to 1 litre with dH20 
B2: 6X Agarose Gel Eletrophoresis Loading Dye 
0.2S% bromophenol blue 
O.2S% xylene cyanol FF 
30% glycerol 
In deionized water 
B3: Sequencing buffer 
200mM Tris, pH 9.0 
SmMMgCh 
B4: Recombination analysis 
Each of the study participants' full length gag sequence was analyzed for recombination 
using REGA version 6.4.1, a software program which compares each nucleotide position 
to other HIV -1 pure subtype and CRF reference sequences to determine whether there is 
sufficient phylogenetic signal to classify the sequence as a pure subtype of CRF, 
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Appendix C: Immunology Techniques 
Peptide sets 
The peptide sets used in the cross-clade study belong to Gag subtype A, Gag subtype D, 
Gag subtype B, Gag C Du422 (South African subtype C) and Gag subtype C China. A 
pool and matrix approach was used in which five pools were made up for each of the 
five peptide variants (Table Cl) and twenty-four matrices were designed to include all 
the single Gag peptides, which make up the five different peptide variants (Table C2). 
The consensus Gag B peptides were available as Img lyophilized peptides while as the 
other four peptide variants were supplied at 500flg/peptide. Single peptides from the five 
clades were reconstituted to 10 fll aliquots of 10mg/ml stocks and then further 
reconstituted to 30flg/ml and stored at -80°C. The peptides were used at a final 
concentration of 1.5flg/ml in the ELISpot assay. 
Peptides were confirmed by the IFN-y ELISpot assay using single peptides to identify 
specific epitope stretches . 
CEF peptide pool and PHA were used as positive controls on all tested PBMCs. The 
CEF peptide pool constituted a panel of 32 8-1 I-mer CMV, EBV and Flu virus peptide 
epitopes recognized by CD8+ T cells. The pool was reconstituted at 20flg/ml in 90% 
PBSIl 0% DMSO and stored at -80°C. 
T~ble Cl Gag pools 
Pool 1 Pool 2 Pool 3 Pool 4 PoolS 
lGag C1 Du422 1-24 25-48 149-72 73-96 97-120 
Gag C2 China 1-24 25-48 149-72 73-96 97-119 
GagB 1-24 25-48 149-72 73-96 97-123 
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A total of 40 asymptomatic HIV -1 subtype C infected individuals were enrolled in 
the study: 20 samples were stored at NICD sample repository and the other 20 at the 
IIDMM 
Assay protocol 
The ELISpot assays were conducted for screening of peptide responses using a panel 
of peptide described in Cl and C2. PBMC from NICD blood donor (QC sample-
NICD 063) was used as a positive control sample for each plate. The QC sample had 
been tested against PHA and CEF and was a known responder and therefore used as a 
positive control. 
Participants' PBMCs were thawed as described in Chapter 3 and tested in duplicate 
against each Gag peptide pool, once against each Gag matrix and twice against CEF 
and PHA (plate layout in Table C3). Eight negative control wells, four positive 
control wells and four peptide control wells were used. 
The negative control well  consisted of six unstimulated PBMC and two unstimulated 
wells for the QC sample per plate. Each plate also had six wells containing RIO 
(media only). 
Positive control wells consisted of two PHA stimulated PBMC and two PHA 
stimulated wells for the QC sample per plate. The control wells consisted of two CEF 
stimulated PBMC and two CEF stimulated QC sample on each plate. 
Peptide confirmations were performed for those peptides that gave a positive 
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Test acceptance criteria 
A test was regarded as positive when the response was > 1 00 sfu/l06 PBMCs and at 
least 3 times the mean background response. The positive response in the pool was 
supposed to match a response in a matrix pool that shares one of the peptides in the 
pool. 
Fail criteria for the ELISpot assay included anyone or more of the following: 
Greater than 100 spots in the negative control wells 
Grater than 5 spots per well for the wells containing media only 
Less than 400 spots per well for the PHA wells. 
Record keeping 
An ELISpot worksheet (Table C3) was completed with each assay performed. The 
plates were read by the CTL Immunospot Analyzer and data saved on CD plates. All 
completed worksheets and ELI Spot raw data and calculated data were archived at the 
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